<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="pmc-domain-id">2103</journal-id><journal-id journal-id-type="pmc-domain">pharmamdpi</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10385664</article-id><article-id pub-id-type="pmcid-ver">PMC10385664.1</article-id><article-id pub-id-type="pmcaid">10385664</article-id><article-id pub-id-type="pmcaiid">10385664</article-id><article-id pub-id-type="pmid">37514095</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics15071909</article-id><article-id pub-id-type="publisher-id">pharmaceutics-15-01909</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Projection of Target Drug Particle Size in Oral Formulations Using the Refined Developability Classification System (rDCS)</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7918-0865</contrib-id><name name-style="western"><surname>Beran</surname><given-names initials="K">Kristian</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-pharmaceutics-15-01909" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-15-01909" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4725-3107</contrib-id><name name-style="western"><surname>Hermans</surname><given-names initials="E">Eline</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af2-pharmaceutics-15-01909" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4894-7765</contrib-id><name name-style="western"><surname>Holm</surname><given-names initials="R">Ren&#233;</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af3-pharmaceutics-15-01909" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sepassi</surname><given-names initials="K">Kia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af4-pharmaceutics-15-01909" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dressman</surname><given-names initials="J">Jennifer</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-pharmaceutics-15-01909" ref-type="aff">1</xref><xref rid="c1-pharmaceutics-15-01909" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Cirri</surname><given-names initials="M">Marzia</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-15-01909"><label>1</label>Fraunhofer Institute of Translational Medicine and Pharmacology, 60596 Frankfurt am Main, Germany</aff><aff id="af2-pharmaceutics-15-01909"><label>2</label>Janssen Research &amp; Development, Pharmaceutical &amp; Material Sciences, 2340 Beerse, Belgium</aff><aff id="af3-pharmaceutics-15-01909"><label>3</label>Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, 5230 Odense, Denmark</aff><aff id="af4-pharmaceutics-15-01909"><label>4</label>Janssen Research &amp; Development, Discovery Pharmaceutics, La Jolla, CA 92121, USA</aff><author-notes><corresp id="c1-pharmaceutics-15-01909"><label>*</label>Correspondence: <email>jennifer.dressman@itmp.fraunhofer.de</email>; Tel.: +49-(0)-69-7438-6408</corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>7</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2023</year></pub-date><volume>15</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">441865</issue-id><elocation-id>1909</elocation-id><history><date date-type="received"><day>10</day><month>6</month><year>2023</year></date><date date-type="rev-recd"><day>30</day><month>6</month><year>2023</year></date><date date-type="accepted"><day>03</day><month>7</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>07</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>30</day><month>07</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-07-15 03:25:15.840"><day>15</day><month>07</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pharmaceutics-15-01909.pdf"/><abstract><p>Dissolution limitations to oral absorption can occur if the time required for dissolution is longer than the transit time across the small intestine and/or if dissolution is slower than the drug&#8217;s permeation through the gut wall. These limitations most often occur for poorly soluble drugs. A standard method for overcoming dissolution issues is to reduce the particle size of the (solid) drug. Building on the refined Developability Classification System (rDCS), this work establishes a novel set of equations with which the appropriate degree of particle size reduction needed to mitigate dissolution limitations to absorption can be calculated. According to the type of data available, the appropriate equation(s) for each situation can be applied. Three case examples are used to illustrate implementation of the equations: voriconazole, lemborexant and istradefylline. Although for voriconazole (rDCS Class I) target radius (r<sub>target</sub>) estimates indicate that particle size reduction is unnecessary, for lemborexant (rDCS Class I) a radius of &#8804;20 &#181;m would be required to improve absorption. For istradefylline (rDCS Class IIb) the r<sub>target</sub> was approximately 12 &#181;m. Results are commensurate with literature information for these three drugs, signaling that the equations are suitable for application to a wide variety of drug substances.</p></abstract><kwd-group><kwd>oral drug absorption</kwd><kwd>particle size</kwd><kwd>refined developability classification system (rDCS)</kwd><kwd>dissolution limitations</kwd><kwd>transit</kwd><kwd>permeability</kwd></kwd-group><funding-group><award-group><funding-source>European Union&#8217;s Horizon 2020 research and innovation programme</funding-source><award-id>955756</award-id></award-group><funding-statement>This project has received funding from the European Union&#8217;s Horizon 2020 research and innovation programme under the Marie Sk&#322;odowska-Curie grant agreement No. 955756.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-15-01909"><title>1. Introduction</title><p>The dynamic interplay between dissolution rate, solubility and permeability in the gastrointestinal tract (GIT) is fundamental to understanding oral drug absorption and serves as the basis for the Biopharmaceutics Classification System (BCS) [<xref rid="B1-pharmaceutics-15-01909" ref-type="bibr">1</xref>]. Orally administered active pharmaceutical ingredients (APIs) must first dissolve in the GI fluids and be absorbed through the gut wall to enter the systemic circulation and subsequently reach their pharmacological target. Dissolution rate limitations to oral drug absorption can occur if the time required for dissolution of an API is longer than the transit time across the absorptive sites in the GIT and/or if dissolution in the GI fluids is significantly slower than the drug&#8217;s permeation through the intestinal epithelium [<xref rid="B2-pharmaceutics-15-01909" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceutics-15-01909" ref-type="bibr">3</xref>]. The dissolution process of solids applying a diffusion layer model was first described by Noyes and Whitney in 1897 and modified by Nernst and Brunner in the early 1900s [<xref rid="B4-pharmaceutics-15-01909" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceutics-15-01909" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceutics-15-01909" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceutics-15-01909" ref-type="bibr">7</xref>]. The Noyes&#8211;Whitney/Nernst&#8211;Brunner equation describes the mass transfer rate from the dissolving surface into the fluid, which is dependent on the surface area exposed to the dissolution medium, the hydrodynamic conditions, the diffusion coefficient, and the thermodynamic solubility of the dissolving molecule. Due to the reciprocal relationship between particle radius and total powder surface area, dissolution rates can be increased through particle size reduction. In cases where dissolution is slower than permeation, the particle size distribution can have a significant impact on the bioavailability of APIs formulated as solid or suspension formulations, necessitating appropriate particle size specifications to ensure efficacious, safe, and reproducible therapy [<xref rid="B8-pharmaceutics-15-01909" ref-type="bibr">8</xref>]. </p><p>The Developability Classification System (DCS) and refined Developability Classification System (rDCS) are tools for assessing the developability of new APIs, including the probability of dissolution rate limitations and target particle size [<xref rid="B9-pharmaceutics-15-01909" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceutics-15-01909" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-15-01909" ref-type="bibr">11</xref>]. </p><p>The DCS was introduced in 2010 and has since found widespread application in both the pharmaceutical industry and academia to predict biopharmaceutical challenges and limitations to oral drug absorption. As an adaption of the BCS, the DCS was conceived specifically to address the demands of drug development and guide formulation strategies to guarantee adequate in vivo drug exposures in (pre-) clinical studies. The DCS classifies APIs into five classes according to the key drivers for absorption: dose, intestinal solubility, and permeability [<xref rid="B9-pharmaceutics-15-01909" ref-type="bibr">9</xref>]. High small intestinal solubility and permeability result in a low risk of incomplete absorption for APIs in class I, such as paracetamol, whereas permeability limitations can be expected for APIs in class III, such as low-dose acyclovir [<xref rid="B9-pharmaceutics-15-01909" ref-type="bibr">9</xref>]. Based on the concept that solubility and permeability are to a certain degree compensatory, the DCS introduced the solubility-limited absorbable dose (SLAD), thereby splitting DCS class II into IIa and IIb for dissolution rate limited APIs (e.g., mefenamic acid) and solubility-limited APIs (e.g., griseofulvin), respectively [<xref rid="B9-pharmaceutics-15-01909" ref-type="bibr">9</xref>]. APIs belonging to class IV, such as high-dose acyclovir, present challenges in formulation development due to both limited solubility and permeability [<xref rid="B9-pharmaceutics-15-01909" ref-type="bibr">9</xref>]. In addition to the revised classification procedure, another innovation of the DCS was the implementation of a calculated target particle size (&#8220;r<sub>target</sub>&#8221;) based on the Dissolution number (Dn), below which dissolution rate limitations can be mitigated [<xref rid="B9-pharmaceutics-15-01909" ref-type="bibr">9</xref>].</p><p>To provide a toolbox specifically tailored to the early stages in oral drug development, the DCS was further expanded into the rDCS. An investigational decision tree with standard and customized investigations to better account for the heterogeneity of APIs in the development pipeline was introduced [<xref rid="B10-pharmaceutics-15-01909" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-15-01909" ref-type="bibr">11</xref>]. The rDCS standard investigations are based on the classical DCS but incorporate the following modifications [<xref rid="B10-pharmaceutics-15-01909" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-15-01909" ref-type="bibr">11</xref>]: <list list-type="simple"><list-item><label>(i)</label><p>The calculation of the dose-to-solubility (D/S) ratio utilizes a standard dose range (5, 50, and 500 mg) instead of a fixed dose, since in preclinical development the human therapeutic dose has typically not yet been defined.</p></list-item><list-item><label>(ii)</label><p>The solubility in fasted state human intestinal fluid (FaHIF) is estimated through a correlation between in vitro solubilities in in-house biopredictive media.</p></list-item><list-item><label>(iii)</label><p>The effective human permeability (P<sub>eff</sub>) is estimated by establishing a correlation between in-house permeability data and reported permeabilities in human volunteers.</p></list-item></list></p><p>The standard investigations indicate whether the risk associated with the development of the API as an immediate release (IR) formulation will be high, medium or low. Depending on the risk analysis and the API&#8217;s physicochemical properties, further customized investigations may be necessary to fully capture the developability risk and make meaningful recommendations about the formulation strategy selection. Customized investigations include small-scale biorelevant supersaturation/precipitation assays for weak bases or salts of weak acids that are classified as rDCS class IIb or IV. For APIs classified as rDCS class IIa or class I/III, but with an aqueous solubility below 100 &#181;g/mL, more extensive dissolution rate analysis, involving small scale intrinsic dissolution rate (IDR) experiments, is recommended. Following the rDCS strategy, the dissolution rate constant (k<sub>diss</sub>) is compared with the permeation rate constant (k<sub>perm</sub>) to estimate whether dissolution or permeation will be rate-limiting to oral absorption [<xref rid="B10-pharmaceutics-15-01909" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-15-01909" ref-type="bibr">11</xref>].</p><p>In this work we explored and compared different ways of estimating the API particle size, r<sub>target</sub>, below which its absorption from an immediate release solid oral dosage form will not be impeded by a low dissolution rate. Building on the DCS and rDCS approaches to assess dissolution rate limitations, a new set of analytically solvable equations for the estimation of r<sub>target</sub> was developed. Results for three APIs (voriconazole, lemborexant and istradefylline) covering a broad range of solubility in fasted state simulated intestinal fluid (FaSSIF V1) were compared. </p></sec><sec id="sec2-pharmaceutics-15-01909"><title>2. Theoretical Section</title><p>In this section, various approaches to calculation of r<sub>target</sub> are shown. Detailed derivations of the equations presented can be found in <xref rid="app1-pharmaceutics-15-01909" ref-type="app">Supplementary Materials</xref>.</p><sec id="sec2dot1-pharmaceutics-15-01909"><title>2.1. Dissolution/Transit Balance: Target Particle Size Estimations Based on the Dissolution Number and Solubility </title><p>The Dissolution Number, Dn, is a dimensionless number developed in a microscopic mass balance approach to estimate the fraction of dose absorbed from suspensions and assess the probability of dissolution rate limitations to oral absorption [<xref rid="B12-pharmaceutics-15-01909" ref-type="bibr">12</xref>]. The value is an integral part of the BCS and DCS and represents the relative rate of dissolution to axial convection, expressed as the ratio of intestinal residence time (Equation (1)) to dissolution time (Equation (2)) from particles with a defined initial particle radius r<sub>0</sub> [<xref rid="B1-pharmaceutics-15-01909" ref-type="bibr">1</xref>,<xref rid="B12-pharmaceutics-15-01909" ref-type="bibr">12</xref>]. The Dn can be calculated from Equations (3) and (4):<disp-formula id="FD1-pharmaceutics-15-01909"><label>(1)</label><mml:math id="mm1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="sans-serif">&#960;</mml:mi><mml:msup><mml:mrow><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">L</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Q</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD2-pharmaceutics-15-01909"><label>(2)</label><mml:math id="mm2" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD3-pharmaceutics-15-01909"><label>(3)</label><mml:math id="mm3" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>&#183;</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">&#961;</mml:mi></mml:mrow></mml:mfrac><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD4-pharmaceutics-15-01909"><label>(4)</label><mml:math id="mm4" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula>
where T<sub>si</sub> is the mean small intestinal transit time, R<sub>si</sub> is the small intestinal radius, L<sub>si</sub> is the small intestinal length, Q is the intestinal fluid flow rate, T<sub>diss</sub> is the time for a particle to dissolve, k<sub>diss</sub> is the dissolution rate constant, r<sub>0</sub> is the initial particle radius, h<sub>particle</sub> is the thickness of the aqueous boundary layer (ABL), &#961; is the API density, D is the diffusion coefficient and C<sub>S</sub> is the thermodynamic solubility [<xref rid="B1-pharmaceutics-15-01909" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceutics-15-01909" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceutics-15-01909" ref-type="bibr">3</xref>,<xref rid="B12-pharmaceutics-15-01909" ref-type="bibr">12</xref>].</p><p>T<sub>si</sub> is a physiological parameter mainly determined by GI motility and its underlying intra- and interindividual variability. For the calculations in this work, T<sub>si</sub> was set to 3.32 h, in line with the DCS and rDCS calculations [<xref rid="B9-pharmaceutics-15-01909" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceutics-15-01909" ref-type="bibr">10</xref>]. In certain circumstances T<sub>si</sub> may need to be adjusted, e.g., if it is known that an excipient or co-administered API affects T<sub>si</sub> [<xref rid="B13-pharmaceutics-15-01909" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceutics-15-01909" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-15-01909" ref-type="bibr">15</xref>], in certain disease states, or if the drug has an &#8220;absorption window&#8221;. </p><p>Since the dissolution rate, and hence T<sub>diss</sub>, can be modulated through particle size adjustment, they are important variables in the development of oral dosage forms. The reciprocal of T<sub>diss</sub> is referred to as k<sub>diss</sub> (Equations (5) and (6)) [<xref rid="B2-pharmaceutics-15-01909" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceutics-15-01909" ref-type="bibr">3</xref>], which can be derived by rearrangement of the Noyes&#8211;Whitney/Nernst&#8211;Brunner equation under key assumptions regarding the total powder surface area (A<sub>powder</sub>), sink conditions, and the thickness of the ABL of the dissolving particle (h<sub>particle</sub>), as set out in <xref rid="pharmaceutics-15-01909-t001" ref-type="table">Table 1</xref>. </p><p>In the literature, h<sub>particle</sub> has been assumed to be equal to the particle radius for small particles [<xref rid="B17-pharmaceutics-15-01909" ref-type="bibr">17</xref>]. As the particle size increases, h<sub>particle</sub> tends to approach a constant value that is small relative to r<sub>0</sub> [<xref rid="B18-pharmaceutics-15-01909" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-15-01909" ref-type="bibr">19</xref>,<xref rid="B21-pharmaceutics-15-01909" ref-type="bibr">21</xref>]. For particles with r<sub>0</sub> &lt; 30 &#181;m, h<sub>particle</sub> is often assumed to equal the particle radius, whereas for r<sub>0</sub> &#8805; 30 &#181;m cases, h<sub>particle</sub> is often assumed to be constant and set to, e.g., 30 &#181;m [<xref rid="B3-pharmaceutics-15-01909" ref-type="bibr">3</xref>,<xref rid="B18-pharmaceutics-15-01909" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-15-01909" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceutics-15-01909" ref-type="bibr">20</xref>]. This 30 &#181;m cut-off was approximated by calculating the ABL thickness of a rotating disk of compressed API [<xref rid="B18-pharmaceutics-15-01909" ref-type="bibr">18</xref>]. Depending on r<sub>0</sub>, the h<sub>particle</sub> value can be adjusted in the k<sub>diss</sub> equation as shown in Equations (5) and (6) [<xref rid="B3-pharmaceutics-15-01909" ref-type="bibr">3</xref>].
<disp-formula id="FD5-pharmaceutics-15-01909"><label>(5)</label><mml:math id="mm5" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo>&#183;</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">&#961;</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mspace linebreak="newline"/><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>,</mml:mo><mml:mo>&#160;</mml:mo><mml:msub><mml:mi mathvariant="normal">h</mml:mi><mml:mtext>particle</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD6-pharmaceutics-15-01909"><label>(6)</label><mml:math id="mm6" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>&#183;</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">&#961;</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mspace linebreak="newline"/><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&#8805;</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>,</mml:mo><mml:mo>&#160;</mml:mo><mml:msub><mml:mi mathvariant="normal">h</mml:mi><mml:mtext>particle</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>Based on the relationship between particle size, dissolution rate and solubility implied by the Dn, Butler and Dressman introduced Equation (7) for the calculation of r<sub>target</sub> [<xref rid="B9-pharmaceutics-15-01909" ref-type="bibr">9</xref>]. In the following, this approach is referred to as the &#8220;dissolution/transit balance approach&#8221;, which answers the question: How low does r<sub>target</sub> need to be for complete dissolution of the dose within the intestinal transit time under sink conditions? A target Dn of 1 was set, corresponding to complete dissolution of the dose within the small intestinal transit time (assuming T<sub>si</sub> = 3.32 h) under sink conditions. The r<sub>target</sub> values calculated from the Dn are especially relevant for APIs in rDCS class IIa and may also be relevant for low solubility (&lt;100 &#181;g/mL) APIs in class I and III, for which a low dose can lead to a D/S ratio of &lt;500 mL. Equation (8) is a modified version of Equation (7) which fixes h<sub>particle</sub> = 30 &#181;m when the particle size exceeds 30 &#181;m. Both equations can be applied to a given drug, subsequently identifying the most relevant r<sub>target</sub> value from the results.
<disp-formula id="FD7-pharmaceutics-15-01909"><label>(7)</label><mml:math id="mm7" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msqrt><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi></mml:mrow></mml:mfrac></mml:msqrt></mml:mrow><mml:mspace linebreak="newline"/><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>,</mml:mo><mml:mo>&#160;</mml:mo><mml:msub><mml:mi mathvariant="normal">h</mml:mi><mml:mtext>particle</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD8-pharmaceutics-15-01909"><label>(8)</label><mml:math id="mm8" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mspace linebreak="newline"/><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&#8805;</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>,</mml:mo><mml:mo>&#160;</mml:mo><mml:msub><mml:mi mathvariant="normal">h</mml:mi><mml:mtext>particle</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula></p></sec><sec id="sec2dot2-pharmaceutics-15-01909"><title>2.2. Dissolution/Transit Balance: Target Particle Size Estimates Based on the Dissolution Number and Intrinsic Dissolution Rate </title><p>Rosenberger et al. published an equation for k<sub>diss</sub> based on the intrinsic dissolution rate (IDR) rather than C<sub>S</sub> (Equation (9)) [<xref rid="B10-pharmaceutics-15-01909" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-15-01909" ref-type="bibr">11</xref>]. Applying the h<sub>particle</sub> assumption for larger particles with r<sub>0</sub> &#8805; 30 &#181;m (h<sub>particle</sub> = 30 &#181;m) results in Equation (10).
<disp-formula id="FD9-pharmaceutics-15-01909"><label>(9)</label><mml:math id="mm9" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">R</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">k</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi></mml:mrow></mml:mfrac><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mspace linebreak="newline"/><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>,</mml:mo><mml:mo>&#160;</mml:mo><mml:msub><mml:mi mathvariant="normal">h</mml:mi><mml:mtext>particle</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD10-pharmaceutics-15-01909"><label>(10)</label><mml:math id="mm10" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">R</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">k</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi></mml:mrow></mml:mfrac><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mspace linebreak="newline"/><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&#8805;</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>,</mml:mo><mml:mo>&#160;</mml:mo><mml:msub><mml:mi mathvariant="normal">h</mml:mi><mml:mtext>particle</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>In these equations k<sub>IDR</sub> is the IDR rate constant, which accounts for the solvent kinematic viscosity, rotational speed of the compressed disk, diffusion coefficient, particle size and API density [<xref rid="B10-pharmaceutics-15-01909" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-15-01909" ref-type="bibr">11</xref>]. Therefore, k<sub>IDR</sub> corrects for differences in experimental conditions that influence the measured IDR value. The ABL thickness of the rotating disk (h<sub>disk</sub>) can be estimated according to Equation (11):<disp-formula id="FD11-pharmaceutics-15-01909"><label>(11)</label><mml:math id="mm11" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">k</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>4.98</mml:mn><mml:mo>&#183;</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="sans-serif">&#957;</mml:mi></mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:msup><mml:mo>&#183;</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:msup><mml:mo>&#183;</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></disp-formula>
where &#957; is the solvent kinematic viscosity and the stirring rate is expressed as revolutions per minute (RPM) [<xref rid="B22-pharmaceutics-15-01909" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceutics-15-01909" ref-type="bibr">23</xref>]. When k<sub>diss</sub> is based on the IDR, two modified Dn equations result (Equations (12) and (13)):<disp-formula id="FD12-pharmaceutics-15-01909"><label>(12)</label><mml:math id="mm12" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">k</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi></mml:mrow></mml:mfrac><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mspace linebreak="newline"/><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>,</mml:mo><mml:mo>&#160;</mml:mo><mml:msub><mml:mi mathvariant="normal">h</mml:mi><mml:mtext>particle</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD13-pharmaceutics-15-01909"><label>(13)</label><mml:math id="mm13" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">k</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi></mml:mrow></mml:mfrac><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mspace linebreak="newline"/><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&#8805;</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>,</mml:mo><mml:mo>&#160;</mml:mo><mml:msub><mml:mi mathvariant="normal">h</mml:mi><mml:mtext>particle</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>Through rearrangement of Equations (12) and (13), new r<sub>target</sub> equations based on Dn and IDR can be obtained (Equations (14) and (15)).
<disp-formula id="FD14-pharmaceutics-15-01909"><label>(14)</label><mml:math id="mm14" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msqrt><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">k</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi></mml:mrow></mml:mfrac></mml:msqrt></mml:mrow><mml:mspace linebreak="newline"/><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>,</mml:mo><mml:mo>&#160;</mml:mo><mml:msub><mml:mi mathvariant="normal">h</mml:mi><mml:mtext>particle</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD15-pharmaceutics-15-01909"><label>(15)</label><mml:math id="mm15" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">k</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mspace linebreak="newline"/><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&#8805;</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>,</mml:mo><mml:mo>&#160;</mml:mo><mml:msub><mml:mi mathvariant="normal">h</mml:mi><mml:mtext>particle</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula></p></sec><sec id="sec2dot3-pharmaceutics-15-01909"><title>2.3. Dissolution/Permeation Balance: Target Particle Size Estimates Based on k<sub>diss</sub>/k<sub>perm</sub> and Solubility </title><p>The dissolution rate analysis can be extended by a novel approach equating the maximum dissolution rate and maximum permeation rate (Equation (16)) [<xref rid="B3-pharmaceutics-15-01909" ref-type="bibr">3</xref>]. The maximum dissolution rate term (based on the assumptions listed in <xref rid="pharmaceutics-15-01909-t001" ref-type="table">Table 1</xref>) is defined by k<sub>diss</sub> and the dose, while the maximum permeation rate is driven by the maximum luminal concentration (expressed as the amount of drug that can be dissolved in the available volume of intestinal fluid, m<sub>dissolved</sub>) and its permeation rate constant (k<sub>perm</sub>) [<xref rid="B3-pharmaceutics-15-01909" ref-type="bibr">3</xref>]. For most rDCS class I and III drugs, m<sub>dissolved</sub> equals the dose because the drug is expected to dissolve completely in the intestinal fluid. For rDCS class II and IV drugs, the solubility rather than the dose represents the limiting factor, such that m<sub>dissolved</sub> will equal the solubility multiplied by the intestinal fluid volume (assumed to be effectively 500 mL). </p><p>The k<sub>perm</sub> equation (Equation (17)) can be derived from the Absorption Number (An, Equation (30)), which represents the ratio of the radial absorption rate to axial convection rate [<xref rid="B12-pharmaceutics-15-01909" ref-type="bibr">12</xref>]. Equations (18) and (19) are obtained by integrating the k<sub>diss</sub> equations for r &lt; 30 &#181;m and r &#8805; 30 &#956;m cases (Equations (5) and (6)) as well as the k<sub>perm</sub> equation (Equation (17)) into Equation (16).
<disp-formula id="FD16-pharmaceutics-15-01909"><label>(16)</label><mml:math id="mm16" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD17-pharmaceutics-15-01909"><label>(17)</label><mml:math id="mm17" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">F</mml:mi><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD18-pharmaceutics-15-01909"><label>(18)</label><mml:math id="mm18" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo>&#183;</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">&#961;</mml:mi></mml:mrow></mml:mfrac><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">F</mml:mi><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mspace linebreak="newline"/><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>,</mml:mo><mml:mo>&#160;</mml:mo><mml:msub><mml:mi mathvariant="normal">h</mml:mi><mml:mtext>particle</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD19-pharmaceutics-15-01909"><label>(19)</label><mml:math id="mm19" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>&#183;</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">&#961;</mml:mi></mml:mrow></mml:mfrac><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">F</mml:mi><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mspace linebreak="newline"/><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&#8805;</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>,</mml:mo><mml:mo>&#160;</mml:mo><mml:msub><mml:mi mathvariant="normal">h</mml:mi><mml:mtext>particle</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>In addition to the variables that have been defined earlier, DF is the degree of flatness of the intestine and P<sub>eff</sub> is the estimated human effective small intestinal permeability. </p><p>By rearranging Equations (18) and (19) for r<sub>0</sub>, new r<sub>target</sub> equations (Equations (20) and (21)) can be derived, which will subsequently be referred to as the &#8220;dissolution/permeation balance approach&#8221;. This approach provides an answer to the question: How low does r<sub>target</sub> need to be for permeation rather than dissolution to become rate limiting?
<disp-formula id="FD20-pharmaceutics-15-01909"><label>(20)</label><mml:math id="mm20" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msqrt><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:msub><mml:mrow><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">F</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi><mml:msub><mml:mrow><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:msqrt></mml:mrow><mml:mspace linebreak="newline"/><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>,</mml:mo><mml:mo>&#160;</mml:mo><mml:msub><mml:mi mathvariant="normal">h</mml:mi><mml:mtext>particle</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD21-pharmaceutics-15-01909"><label>(21)</label><mml:math id="mm21" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:msub><mml:mrow><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">F</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi><mml:msub><mml:mrow><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mspace linebreak="newline"/><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&#8805;</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>,</mml:mo><mml:mo>&#160;</mml:mo><mml:msub><mml:mi mathvariant="normal">h</mml:mi><mml:mtext>particle</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula></p></sec><sec id="sec2dot4-pharmaceutics-15-01909"><title>2.4. Dissolution/Permeation Balance: Target Particle Size Estimates Based on k<sub>diss</sub>/k<sub>perm</sub> and Intrinsic Dissolution Rate </title><p>An alternative approach is to apply the k<sub>diss</sub> based on the IDR (Equations (9) and (10)) to estimate the maximal dissolution rate in Equation (16). Through rearrangement of these equations, further r<sub>target</sub> equations based on the dissolution/permeation balance and the IDR as input can be derived (Equations (22) and (23)):<disp-formula id="FD22-pharmaceutics-15-01909"><label>(22)</label><mml:math id="mm22" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msqrt><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">k</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:msub><mml:mrow><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">F</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi><mml:msub><mml:mrow><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:msqrt></mml:mrow><mml:mspace linebreak="newline"/><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>,</mml:mo><mml:mo>&#160;</mml:mo><mml:msub><mml:mi mathvariant="normal">h</mml:mi><mml:mtext>particle</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD23-pharmaceutics-15-01909"><label>(23)</label><mml:math id="mm23" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">k</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:msub><mml:mrow><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">F</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi><mml:msub><mml:mrow><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mspace linebreak="newline"/><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&#8805;</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>,</mml:mo><mml:mo>&#160;</mml:mo><mml:msub><mml:mi mathvariant="normal">h</mml:mi><mml:mtext>particle</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#181;</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula></p></sec><sec id="sec2dot5-pharmaceutics-15-01909"><title>2.5. Dissolution/Permeation Balance: Target Particle Size Estimates Based on Powder Surface Area and Intrinsic Dissolution Rate </title><p>The dissolution rate from a rotating disk of compressed API can be calculated by multiplying the IDR by the constant disk surface area (A<sub>disk</sub>). This approach can also be applied to the dissolution of a powder, whereby the powder dissolution rate can be estimated from the IDR and the total powder surface area (A<sub>powder</sub>) according to Equation (24):<disp-formula id="FD24-pharmaceutics-15-01909"><label>(24)</label><mml:math id="mm24" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>This definition of the dissolution rate can be related to the maximum permeation rate analogous to Equation (16). Integration of the A<sub>powder</sub> equation presented in <xref rid="pharmaceutics-15-01909-t001" ref-type="table">Table 1</xref> yields Equation (25), and rearrangement results in another r<sub>target</sub> equation (Equation (26)).
<disp-formula id="FD25-pharmaceutics-15-01909"><label>(25)</label><mml:math id="mm25" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mo>&#183;</mml:mo><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">F</mml:mi><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD26-pharmaceutics-15-01909"><label>(26)</label><mml:math id="mm26" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:msub><mml:mrow><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">F</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi><mml:msub><mml:mrow><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mspace linebreak="newline"/><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi mathvariant="normal">h</mml:mi><mml:mtext>particle</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">h</mml:mi><mml:mtext>disk</mml:mtext></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>The dissolution rate term using A<sub>powder</sub> assumes that the disk IDR is a constant which can be projected to powder dissolution without corrections. Thus, the approach assumes that h<sub>particle</sub> during powder dissolution equals h<sub>disk</sub>, noting that h<sub>disk</sub> values under common experimental conditions (100 rpm) often exceed the 30 &#181;m cut-off [<xref rid="B22-pharmaceutics-15-01909" ref-type="bibr">22</xref>].</p></sec><sec id="sec2dot6-pharmaceutics-15-01909"><title>2.6. Summary of Target Particle Size Equations</title><p>In this analysis, nine key equations, including eight new ones, were derived for the calculation of the target particle size in early drug development. The theory behind the approaches presented in <xref rid="sec2dot1-pharmaceutics-15-01909" ref-type="sec">Section 2.1</xref>, <xref rid="sec2dot2-pharmaceutics-15-01909" ref-type="sec">Section 2.2</xref>, <xref rid="sec2dot3-pharmaceutics-15-01909" ref-type="sec">Section 2.3</xref>, <xref rid="sec2dot4-pharmaceutics-15-01909" ref-type="sec">Section 2.4</xref> and <xref rid="sec2dot5-pharmaceutics-15-01909" ref-type="sec">Section 2.5</xref> is visualized in <xref rid="pharmaceutics-15-01909-f001" ref-type="fig">Figure 1</xref>. </p><p>The equations, summarized in <xref rid="pharmaceutics-15-01909-t002" ref-type="table">Table 2</xref>, are based either on C<sub>S</sub> or IDR as input parameters, include different assumptions about the ABL thickness and were constructed to examine the dissolution/transit and dissolution/permeation balance in various scenarios, as shown in <xref rid="pharmaceutics-15-01909-f001" ref-type="fig">Figure 1</xref>. To facilitate implementation of the equations, an Excel spreadsheet for automated calculation of all r<sub>target</sub> values is provided as <xref rid="app1-pharmaceutics-15-01909" ref-type="app">Supplementary Materials</xref>. The permeation/transit balance is not interrogated in this work, as neither is influenced directly by particle size.</p><p><xref rid="pharmaceutics-15-01909-f002" ref-type="fig">Figure 2</xref> provides guidance on which equation may be best suited for a given case, noting that it may be prudent to compare r<sub>target</sub> values calculated using different approaches to capture the most relevant particle size. Starting from the outermost shell, the first step involves selecting the preferred input parameter for the r<sub>target</sub> calculations, which can be either solubility (C<sub>S</sub>) or intrinsic dissolution rate (IDR). Depending on the availability of experimental data, particularly in cases where the rDCS recommends customized IDR experiments, values calculated from C<sub>S</sub> and IDR should be compared to understand whether factors like wetting of the API surface or reactions in the ABL influence the dissolution kinetics. </p><p>The second step involves estimating whether in vivo dissolution will take place under sink conditions. If sink conditions are expected to apply, the dissolution/transit balance approach should be used and, alternatively, if sink conditions are not expected to be met, the dissolution/permeation balance approach is recommended. Sink conditions are likely to be maintained if the permeability of the API is high and/or if the D/S ratio is low such that concentrations in the intestinal fluid are kept well below one-third of the saturation concentration. Conversely, sink conditions are less likely to apply if the permeability is medium to low and/or if the D/S ratio is high. In the innermost shells, a suitable assumption regarding the ABL thickness is chosen. If the calculated r<sub>target</sub> is &lt;30 &#181;m, the assumption h<sub>particle</sub> = r<sub>0</sub> is an appropriate option. On the other hand, if the calculated r<sub>target</sub> is &#8805;30 &#181;m, the assumptions h<sub>particle</sub> = 30 &#181;m or h<sub>particle</sub> = h<sub>disk</sub> are appropriate. At this point, the recommended r<sub>target</sub> equation(s) is selected.</p></sec></sec><sec id="sec3-pharmaceutics-15-01909"><title>3. Materials and Methods</title><sec id="sec3dot1-pharmaceutics-15-01909"><title>3.1. Chemicals </title><p>Voriconazole (batch FV291011901, purity &gt; 99%) and lemborexant (batch 0000041758, purity &gt; 99%) were purchased from Biosynth Carbosynth (Compton, UK). Istradefylline (batch 16512, purity &gt; 99%) was purchased from MedChemExpress LLC (Monmouth Junction, NJ, USA). The chemical structures of the three APIs are shown in <xref rid="pharmaceutics-15-01909-f003" ref-type="fig">Figure 3</xref>.</p><p>Acetonitrile (ACN gradient grade for liquid chromatography), dimethylsulfoxide (DMSO for liquid chromatography), hydrochloric acid (5 N HCl) and sodium hydroxide (5 N NaOH) were purchased from Merck KGaA (Darmstadt, Germany). Trifluoroacetic acid (TFA) was purchased from Thermo Fisher Scientific (Rockford, IL, USA). FaSSIF/FeSSIF/FaSSGF powder and FaSSIF buffer concentrate were purchased from Biorelevant.com Ltd. (London, UK). Water was purified with a Milli-Q Advantage A10 Water Purification System (Merck KGaA, Darmstadt, Germany). </p><p>FaSSIF V1 was prepared according to the instructions provided by Biorelevant.com [<xref rid="B24-pharmaceutics-15-01909" ref-type="bibr">24</xref>]. First, a FaSSIF blank buffer was prepared by diluting the buffer concentrate with Milli-Q water. The final medium was obtained by dissolving FaSSIF powder in the blank buffer and equilibrating the medium at room temperature for 2 h. The pH was measured and adjusted to pH 6.50 &#177; 0.05 using hydrochloric acid or sodium hydroxide, if necessary.</p></sec><sec id="sec3dot2-pharmaceutics-15-01909"><title>3.2. Physicochemical Characterization</title><sec id="sec3dot2dot1-pharmaceutics-15-01909"><title>3.2.1. Dissociation Constant (pK<sub>a</sub>)</title><p>The pK<sub>a</sub> values of voriconazole, lemborexant and istradefylline were determined at Pion Inc (UK) Ltd. (Forest Row, UK). A high-throughput spectrometric screening assay (Fast UV method) using the SiriusT3 (Pion Inc., Billerica, MA, USA) was applied. Samples were titrated under varying water/methanol ratios and apparent pK<sub>a</sub> values were extrapolated using the Yasuda&#8211;Shedlovsky extrapolation. The experimental details are provided in <xref rid="app1-pharmaceutics-15-01909" ref-type="app">Supplementary Materials</xref>. Measured pK<sub>a</sub> values are presented as means (&#177;SD) and were compared to literature values as well as in silico predictions using the software ADMET Predictor version 9 (Simulations Plus Inc., Lancaster, CA, USA) and ACD/Labs Release 2021.1.2 (Advanced Chemistry Development Inc., Toronto, ON, Canada).</p></sec><sec id="sec3dot2dot2-pharmaceutics-15-01909"><title>3.2.2. n-Octanol/Water Distribution Coefficient (logD<sub>pH7.4</sub>)</title><p>LogD<sub>pH7.4</sub> values of the three APIs were determined at Pion Inc (UK) Ltd. (Forest Row, UK) using a shake-flask screening method and high performance liquid chromatography with UV detection (HPLC-UV). Samples containing the API were equilibrated between octanol-saturated 0.01 M phosphate buffer at pH 7.4 and buffer-saturated octanol and analyzed by HPLC-UV. The experimental details are provided in <xref rid="app1-pharmaceutics-15-01909" ref-type="app">Supplementary Materials</xref>. Measured logD<sub>pH7.4</sub> values are presented as means (&#177;SD) and were compared to literature values as well as in silico predictions using the software ADMET Predictor version 9 and ACD/Labs Release 2021.1.2.</p></sec></sec><sec id="sec3dot3-pharmaceutics-15-01909"><title>3.3. rDCS Standard Investigations: Solubility Studies</title><p>Equilibrium solubilities of the three APIs in FaSSIF V1 were measured with the shake-flask method, following the ICH M9 guideline on BCS-based biowaivers [<xref rid="B15-pharmaceutics-15-01909" ref-type="bibr">15</xref>]. Briefly, an excess amount of each API was weighed into a 5 mL vial and the assay medium (FaSSIF V1) was added. The resulting suspensions were incubated at 37.0 &#177; 0.5 &#176;C (Memmert Incubator IN750, Memmert GmbH + Co. KG, Schwabach, Germany) and agitated for 24 h at 25 rpm (LABINCO LD76 Digital Rotary Mixer, Labinco BV, Breda, The Netherlands). At 2, 4, 6 and 24 h, samples were drawn and filtered through Acrodisc 13 mm with 0.45 &#181;m PTFE filters (Pall Corporation, Port Washington, NY, USA) after establishing that adsorption of the APIs onto the filters was less than 5%. Before sampling, the suspensions were checked visually for the presence of solid particles and the pH was measured (Metrohm 780 pH Meter, Metrohm AG, Herisau, Switzerland). All measured pH values were within the specified range of pH 6.50 &#177; 0.05, so no pH adjustment was necessary. The filtrates were diluted with a 1:1 mixture of ACN and Milli-Q water for analysis using ultra-performance liquid chromatography with UV detection (UPLC-UV). </p><p>Residual solids from the solubility studies were collected after 24 h and examined using X-ray powder diffraction (XRPD) analysis. XRPD patterns of the residual solids were compared to the starting material and literature profiles. A differential scanning calorimetry (DSC) analysis of the input materials was additionally performed. Istradefylline samples were protected from light in all studies using amber vials and aluminum foil to prevent photolysis [<xref rid="B24-pharmaceutics-15-01909" ref-type="bibr">24</xref>]. The experimental details of the UPLC-UV methods and solid state analyses can be found in <xref rid="app1-pharmaceutics-15-01909" ref-type="app">Supplementary Materials</xref>. </p><p>The solubility experiments were performed in triplicate (<italic toggle="yes">n</italic> = 3) and solubilities are presented as means (&#177; SD). The mean values were used as input for the rDCS and r<sub>target</sub> calculations. </p></sec><sec id="sec3dot4-pharmaceutics-15-01909"><title>3.4. rDCS Standard Investigations: Caco-2 Permeability Studies</title><p>In vitro permeability studies were performed at Cyprotex Discovery Ltd. (Macclesfield, UK) using a high-throughput Caco-2 permeability assay. Permeability at 37 &#176;C was assessed from the apical to basolateral side (A&#10233;B) and in opposite direction (B&#10233;A) applying a pH gradient with pH 6.5 in the apical and pH 7.4 in the basolateral compartment (Hanks Balanced Salt Solution, HBSS). After an incubation of 120 min, samples were diluted for analysis via liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Measurements were performed in duplicate and reference compounds of known permeability (atenolol, propanolol and antipyrine) were included as quality controls. Experiments were performed in absence and presence of the P-glycoprotein (P-gp) inhibitor elacridar (10 &#181;M) to study transporter-mediated efflux effects. The dosing solutions contained the API (10 &#181;M) in HBSS, and DMSO in a concentration of &#8804;1% <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>. Lucifer yellow (100 &#181;M) was included as fluorescent integrity marker. Further experimental details are provided in <xref rid="app1-pharmaceutics-15-01909" ref-type="app">Supplementary Materials</xref>.</p><p>The apparent permeability coefficients (P<sub>app</sub>) were calculated according to Equation (27):<disp-formula id="FD27-pharmaceutics-15-01909"><label>(27)</label><mml:math id="mm27" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">Q</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">A</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>
where dQ/dt is the permeation rate of the API across the cell monolayer, C<sub>0</sub> is the starting concentration of the API in the dosing solution and A is the surface area of the cell monolayer [<xref rid="B25-pharmaceutics-15-01909" ref-type="bibr">25</xref>]. The efflux ratios (ERs) were calculated from the B&#10233;A and A&#10233;B P<sub>app</sub> values to estimate whether P-gp mediated efflux was involved in the transport of the APIs. The mass balance (% recovery) was calculated from the sum of the API recovered from the acceptor and donor compartments at the end of the experiment, divided by the initial donor amount [<xref rid="B25-pharmaceutics-15-01909" ref-type="bibr">25</xref>].</p><p>The Caco-2 P<sub>app</sub> values were averaged. P<sub>app</sub>(A&#10233;B) values without inhibitor were converted to effective human in vivo permeability (P<sub>eff</sub>) values using Simcyp Version 21 software (Simcyp Ltd., Sheffield, UK). The built-in literature P<sub>app</sub>&#8211;P<sub>eff</sub> correlation assuming a pH gradient (pH 6.5&#10233;7.4) and passive API permeation with atenolol and propranolol as calibrator substances was used [<xref rid="B26-pharmaceutics-15-01909" ref-type="bibr">26</xref>]. Estimated P<sub>eff</sub> values were used as input for the rDCS and r<sub>target</sub> calculations.</p></sec><sec id="sec3dot5-pharmaceutics-15-01909"><title>3.5. rDCS Customized Investigations: Intrinsic Dissolution Rate </title><sec id="sec3dot5dot1-pharmaceutics-15-01909"><title>3.5.1. Disk Dissolution Studies</title><p>The IDRs of voriconazole and lemborexant in FaSSIF V1 at 37.0 &#177; 0.5 &#176;C were determined using the &#181;DISS Profiler (Pion Inc., Billerica, MA, USA) [<xref rid="B27-pharmaceutics-15-01909" ref-type="bibr">27</xref>]. The experimental design was adapted from a standard experimental protocol published previously [<xref rid="B28-pharmaceutics-15-01909" ref-type="bibr">28</xref>]. Disks (<italic toggle="yes">n</italic> = 3) with a surface area of 0.0707 cm<sup>2</sup> were prepared by compressing the APIs into disk dies. For this, 5 to 10 mg of the API was compressed for 1 min at 50 bar using a Mini-IDR Tablet Compression System (Heath Scientific Co. Ltd., Milton Keynes, UK). Loose powder on the disk surface or die was removed with compressed air. The disks were prepared from the pure crystalline form of voriconazole (form B) and lemborexant (form CS2). With the disk surface facing upwards, the dies were placed into round-shaped magnetic stirrers and transferred into 20 mL assay vials. The vials were placed in a heating block and pre-heated FaSSIF V1 (10 mL) was added to each vial to start the dissolution experiments. The disks were rotated at 100 rpm and concentrations were measured in situ with UV-spectroscopy using fiber optic dip probes. Experiments were performed in triplicate. </p><p>The dissolution curves were truncated at concentrations corresponding to 10% of the solubility to ensure sink conditions and the IDR was calculated from the slope of the dissolution profile according to Equation (28): <disp-formula id="FD28-pharmaceutics-15-01909"><label>(28)</label><mml:math id="mm28" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">k</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:mfrac><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">V</mml:mi><mml:mo>&#183;</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math></disp-formula>
where dC/dt is the slope of the linear concentration-time curve, t is the time, V is the volume of the dissolution medium and A<sub>disk</sub> is the disk surface area [<xref rid="B22-pharmaceutics-15-01909" ref-type="bibr">22</xref>,<xref rid="B27-pharmaceutics-15-01909" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceutics-15-01909" ref-type="bibr">28</xref>]. Measured IDRs were compared to theoretical IDRs calculated from the Levich equation with solubility as input via an unpaired t-test with &#945; = 0.05.</p><p>XRPD analysis of the disks before and after dissolution was performed, and lemborexant disks were additionally analyzed by DSC. The diffractograms and thermograms can be found in <xref rid="app1-pharmaceutics-15-01909" ref-type="app">Supplementary Materials</xref>.</p></sec><sec id="sec3dot5dot2-pharmaceutics-15-01909"><title>3.5.2. Powder Dissolution Studies</title><p>Istradefylline disks could not be prepared because disk compression led to a change in solid state. The IDR of istradefylline was therefore measured (<italic toggle="yes">n</italic> = 4) according to a published powder dissolution method for estimating rotating disk IDRs [<xref rid="B22-pharmaceutics-15-01909" ref-type="bibr">22</xref>,<xref rid="B28-pharmaceutics-15-01909" ref-type="bibr">28</xref>]. Istradefylline was weighed into an assay vial containing a magnetic crossbar stirrer, in an amount corresponding to approximately twice the amount needed to saturate the medium. The vials were placed in a heating block and 20 mL pre-heated FaSSIF V1 (37.0 &#177; 0.5 &#176;C) was added to start the dissolution experiments. The medium was stirred at 100 rpm and concentrations were measured with in situ UV-spectroscopy using fiber optic dip probes until a plateau in the dissolution profile was reached. The vials were protected from light with aluminum foil during the entire experiment. </p><p>The powder IDR was derived using the dissolution curve tool integrated in the AuPRO Software Version 6 (Pion Inc., Billerica, MA, USA) as described in Tsinman et al. [<xref rid="B22-pharmaceutics-15-01909" ref-type="bibr">22</xref>]. </p><p>IDRs are presented as means (&#177;SD). Mean values were used as input for the rDCS and r<sub>target</sub> calculations. </p></sec></sec><sec id="sec3dot6-pharmaceutics-15-01909"><title>3.6. rDCS Calculations </title><sec id="sec3dot6dot1-pharmaceutics-15-01909"><title>3.6.1. rDCS Classification Based on Standard Investigations</title><p>rDCS analysis was performed as described by Rosenberger et al. [<xref rid="B10-pharmaceutics-15-01909" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-15-01909" ref-type="bibr">11</xref>]. The D/S ratios for voriconazole, lemborexant and istradefylline were calculated based on their biorelevant solubility in FaSSIF V1 and the rDCS standard dose range (5, 50 and 500 mg) [<xref rid="B10-pharmaceutics-15-01909" ref-type="bibr">10</xref>]. Additional D/S ratios for usual single doses were also calculated: 200 mg for voriconazole [<xref rid="B29-pharmaceutics-15-01909" ref-type="bibr">29</xref>], 10 mg for lemborexant [<xref rid="B30-pharmaceutics-15-01909" ref-type="bibr">30</xref>] and 20 mg for istradefylline [<xref rid="B31-pharmaceutics-15-01909" ref-type="bibr">31</xref>]. The SLAD was calculated according to Equation (29):<disp-formula id="FD29-pharmaceutics-15-01909"><label>(29)</label><mml:math id="mm29" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">L</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">V</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula>
where C<sub>S</sub> is the measured thermodynamic solubility, V is the assumed effective volume of intestinal fluids (500 mL), and M<sub>p</sub> is the permeability dependent multiplier, which is equal to the An for rDCS Class II drugs [<xref rid="B9-pharmaceutics-15-01909" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceutics-15-01909" ref-type="bibr">10</xref>]. The An can be calculated according to Equation (30):<disp-formula id="FD30-pharmaceutics-15-01909"><label>(30)</label><mml:math id="mm30" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">F</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>The rDCS classification according to the standard investigations was based on the D/S ratios, P<sub>eff</sub> and SLAD.</p></sec><sec id="sec3dot6dot2-pharmaceutics-15-01909"><title>3.6.2. rDCS Customized Investigations: Dissolution Rate Analysis </title><p>The rDCS dissolution rate analysis was conducted according to Rosenberger et al. [<xref rid="B10-pharmaceutics-15-01909" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-15-01909" ref-type="bibr">11</xref>]. For this, k<sub>diss</sub> based on the IDR for a standard particle size of 100 &#181;m was calculated (Equation (15)) and compared to k<sub>perm</sub> (Equation (10)). The kinematic viscosity of the medium (0.00696 cm<sup>2</sup>/s), aqueous diffusion coefficient (predicted with ADMET Predictor version 9), stirring rate (100 rpm), initial particle size (100 &#181;m), API density (predicted with ACD/Labs Release 2021.1.2), and measured IDR were used to calculate k<sub>diss</sub>. Predicted diffusion coefficients and API densities can be found in <xref rid="app1-pharmaceutics-15-01909" ref-type="app">Supplementary Materials</xref>. The estimated P<sub>eff</sub>, degree of flatness (1.7) and small intestinal radius (2 cm) were used for the calculation of k<sub>perm</sub>. </p><p>As an extension of the original rDCS analysis, the equations presented in the Theoretical Section were used to estimate the r<sub>target</sub> values for the three APIs. Additional input values for the r<sub>target</sub> calculations were the measured thermodynamic solubility in FaSSIF V1, the mean small intestinal transit time (3.32 h), target Dn (1), the dose, and m<sub>dissolved</sub> (using the dose for Class I and III APIs; solubility multiplied by 500 mL for Class II and IV). As the usual single doses are known for all three APIs, these doses were chosen for the r<sub>target</sub> calculations, noting that for compounds in preclinical development, the evaluation would typically be made at the rDCS standard doses of 5, 50 and 500 mg.</p></sec></sec></sec><sec sec-type="results" id="sec4-pharmaceutics-15-01909"><title>4. Results</title><sec id="sec4dot1-pharmaceutics-15-01909"><title>4.1. Physicochemical Characterization </title><sec id="sec4dot1dot1-pharmaceutics-15-01909"><title>4.1.1. Dissociation Constant (pK<sub>a</sub>) </title><p>Experimental and literature pK<sub>a</sub> values for voriconazole, lemborexant and istradefylline are summarized in <xref rid="pharmaceutics-15-01909-t003" ref-type="table">Table 3</xref>.</p><p>The pK<sub>a</sub> of lemborexant determined with the Fast UV method was 2.18 &#177; 0.05, noting that the value was associated with a low absorbance in the assay. Comparative literature values were estimated to be &lt;3.5 by capillary electrophoresis [<xref rid="B33-pharmaceutics-15-01909" ref-type="bibr">33</xref>].</p><p>The experimental pK<sub>a</sub> values of voriconazole and istradefylline lay outside the standard titration range of pH 2 to 12. In both cases a pK<sub>a</sub> below the lower calibration limit of the Fast UV method was detected, but not reported. For voriconazole, a basic pK<sub>a</sub> of 1.76 associated with the triazole moiety has been reported in the literature [<xref rid="B32-pharmaceutics-15-01909" ref-type="bibr">32</xref>], while for istradefylline a basic pK<sub>a</sub> of 0.78 has been reported [<xref rid="B31-pharmaceutics-15-01909" ref-type="bibr">31</xref>,<xref rid="B34-pharmaceutics-15-01909" ref-type="bibr">34</xref>].</p><p>For comparison, in silico predicted pK<sub>a</sub> values are tabulated in <xref rid="app1-pharmaceutics-15-01909" ref-type="app">Supplementary Materials</xref>, noting that certain values deviated substantially from the values shown in <xref rid="pharmaceutics-15-01909-t003" ref-type="table">Table 3</xref>.</p></sec><sec id="sec4dot1dot2-pharmaceutics-15-01909"><title>4.1.2. n-Octanol/Water Distribution Coefficient (logD<sub>pH7.4</sub>)</title><p>Experimental logD<sub>pH7.4</sub> and literature logP values for the three APIs are summarized in <xref rid="pharmaceutics-15-01909-t004" ref-type="table">Table 4</xref>. Based on the pK<sub>a</sub> values discussed above, all compounds are uncharged at pH 7.4. Therefore, the logD<sub>pH7.4</sub> and logP values are identical. The experimental values differed from those reported in the literature by less than 10% for voriconazole, and less than 25% for lemborexant and istradefylline. In silico predictions of logP can be found in <xref rid="app1-pharmaceutics-15-01909" ref-type="app">Supplementary Materials</xref>. These differed from the experimental values by less than 45%.</p></sec></sec><sec id="sec4dot2-pharmaceutics-15-01909"><title>4.2. rDCS Standard Investigations: Solubility Studies </title><p>The results of the solubility studies in FaSSIF V1, along with the corresponding crystalline forms, are presented in <xref rid="pharmaceutics-15-01909-t005" ref-type="table">Table 5</xref>.</p><p>The XRPD patterns and DSC thermograms of the starting materials and the residual solids from the solubility studies were identical for all investigated APIs (<xref rid="app1-pharmaceutics-15-01909" ref-type="app">Supplementary Materials</xref>). The following crystalline forms were identified: form B of voriconazole [<xref rid="B35-pharmaceutics-15-01909" ref-type="bibr">35</xref>], form CS2 of lemborexant [<xref rid="B36-pharmaceutics-15-01909" ref-type="bibr">36</xref>], and form I of istradefylline [<xref rid="B37-pharmaceutics-15-01909" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-15-01909" ref-type="bibr">38</xref>]. The crystalline forms were consistent with the forms used in the respective marketed formulations [<xref rid="B30-pharmaceutics-15-01909" ref-type="bibr">30</xref>,<xref rid="B34-pharmaceutics-15-01909" ref-type="bibr">34</xref>,<xref rid="B37-pharmaceutics-15-01909" ref-type="bibr">37</xref>,<xref rid="B39-pharmaceutics-15-01909" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceutics-15-01909" ref-type="bibr">40</xref>]. </p></sec><sec id="sec4dot3-pharmaceutics-15-01909"><title>4.3. rDCS Standard Investigations: Caco-2 Permeability Studies</title><p>Caco-2 P<sub>app</sub> values for both transport directions, with and without inhibitor, as well as derived P<sub>eff</sub> values are summarized in <xref rid="pharmaceutics-15-01909-t006" ref-type="table">Table 6</xref>. Recoveries were &gt;87% (voriconazole), &gt;74% (lemborexant), and &gt;85% (istradefylline). Using antipyrine (P<sub>app</sub>(A&#10233;B) = 43.9 &#215; 10<sup>&#8722;6</sup> cm/s), propranolol (P<sub>app</sub>(A&#10233;B) = 13.0 &#177; 0.7 &#215; 10<sup>&#8722;6</sup> cm/s) and atenolol (P<sub>app</sub>(A&#10233;B) = 0.197 &#177; 0.051 &#215; 10<sup>&#8722;6</sup> cm/s) as comparators, all three substances were considered highly permeable. The efflux ratios were less than 2 for all substances, indicating no significant in vitro P-gp transporter effects [<xref rid="B41-pharmaceutics-15-01909" ref-type="bibr">41</xref>]. P<sub>app</sub>(A&#10233;B) values were converted to P<sub>eff</sub> using propranolol and atenolol as calibrators and resulted in similar predicted values for all three substances.</p></sec><sec id="sec4dot4-pharmaceutics-15-01909"><title>4.4. rDCS Customized Investigations: Intrinsic Dissolution Rate </title><p>The results of the IDR studies in FaSSIF V1, including the corresponding crystalline forms, are presented in <xref rid="pharmaceutics-15-01909-t005" ref-type="table">Table 5</xref>. IDR values and thermodynamic solubilities of the three APIs correlated well (<xref rid="pharmaceutics-15-01909-f004" ref-type="fig">Figure 4</xref>).</p><p>Overlays of the XRPD patterns and the DSC thermograms comparing the starting materials for disk compression and the disks pre- and post-dissolution can be found in <xref rid="app1-pharmaceutics-15-01909" ref-type="app">Supplementary Materials</xref>. The solid state of voriconazole and lemborexant did not change after disk compression and dissolution. Analyses of istradefylline disks using XRPD and DSC indicated a solid state change upon compression. Consequently, the IDR was determined with the powder dissolution method.</p></sec><sec id="sec4dot5-pharmaceutics-15-01909"><title>4.5. rDCS Calculations </title><sec id="sec4dot5dot1-pharmaceutics-15-01909"><title>4.5.1. rDCS Standard Investigations</title><p>The rDCS classifications of voriconazole, lemborexant and istradefylline according to the standard investigations including SLADs can be found in <xref rid="pharmaceutics-15-01909-t005" ref-type="table">Table 5</xref>.</p></sec><sec id="sec4dot5dot2-pharmaceutics-15-01909"><title>4.5.2. rDCS Customized Investigations: Dissolution Rate Analysis</title><p>The dissolution rate analyses, conducted according to Rosenberger et al., are shown in <xref rid="pharmaceutics-15-01909-t007" ref-type="table">Table 7</xref> [<xref rid="B10-pharmaceutics-15-01909" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-15-01909" ref-type="bibr">11</xref>]. For all APIs, k<sub>diss</sub> was smaller than k<sub>perm</sub>, with a rank order of k<sub>diss</sub> (voriconazole) &gt; k<sub>diss</sub> (lemborexant) &gt; k<sub>diss</sub> (istradefylline). The predicted risk for dissolution rate limitations therefore increased from voriconazole to lemborexant and istradefylline, in line with the measured thermodynamic solubilities. The calculated r<sub>target</sub> estimates are displayed in <xref rid="pharmaceutics-15-01909-t008" ref-type="table">Table 8</xref>.</p></sec></sec></sec><sec sec-type="discussion" id="sec5-pharmaceutics-15-01909"><title>5. Discussion</title><p>In early preclinical development, pharmaceutical profiling is an important step in the selection of drug candidates and the subsequent formulation campaign. Typically, in vitro characterization of API candidates, early Physiologically based Biopharmaceutics Modeling (PBBM) and comparative PK studies of formulations in animals support biopharmaceutical research at this stage. The main challenge for the pharmaceutical industry at present is to reduce (or even eliminate) animal testing in biopharmaceutical research while ensuring that the formulation for first-in-human studies is appropriate. The rDCS provides rational and science-based guidance to formulators, while maintaining simplicity as a key element to accommodate the demand for medium to high throughput.</p><p>One of the key elements of the rDCS is identifying an appropriate particle size for oral formulations. This is of special importance, since particle size not only influences the dissolution behavior and bioavailability of many drug substances, but also impacts processability and critical quality attributes of the final product, such as stability, content uniformity and product appearance [<xref rid="B8-pharmaceutics-15-01909" ref-type="bibr">8</xref>]. Building on the existing rDCS framework, new equations for the calculation of target particle size are now introduced to more completely explore the risk of incomplete absorption due to dissolution rate issues and facilitate biopharmaceutical decision-making.</p><sec id="sec5dot1-pharmaceutics-15-01909"><title>5.1. Complementarity of the Dissolution/Transit Balance and Dissolution/Permeation Balance Approach</title><p>Dissolution/transit balance: Particle size recommendations based on the Dn address how to achieve complete dissolution of the API dose in the intestinal fluid within the intestinal transit time [<xref rid="B9-pharmaceutics-15-01909" ref-type="bibr">9</xref>]. When Dn = 1, the dose will dissolve within an intestinal transit time of 3.32 h. This approach relies on the assumption of sink conditions and is therefore best suited for APIs that have high permeability and are thus rapidly absorbed once they dissolve and/or have a low D/S ratio. The assumption is less suitable for APIs with solubility-limited absorption (high D/S ratio) and/or a medium to low permeability. To determine how variability in transit time might affect the absorbed fraction, transit times over the usual range of 2&#8211;5 h can be explored [<xref rid="B42-pharmaceutics-15-01909" ref-type="bibr">42</xref>]. If a formulation is required to dissolve within a shorter time to achieve rapid onset, either the transit time can be shortened or the target Dn raised to account for this. In both cases, lower r<sub>target</sub> values will result. This approach would also be useful for APIs with an absorption window in the intestinal tract [<xref rid="B9-pharmaceutics-15-01909" ref-type="bibr">9</xref>].</p><p>Dissolution/permeation balance: Rosenberger et al. extended the DCS dissolution rate analysis by comparing dissolution (k<sub>diss</sub>) and permeation (k<sub>perm</sub>) rate constants to estimate if the dissolution or permeation rate represents the limiting step in oral drug absorption [<xref rid="B10-pharmaceutics-15-01909" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-15-01909" ref-type="bibr">11</xref>]. However, equality of the rate constants does not necessarily mean that the dissolution and permeation rates are the same: whereas the main driving force for dissolution is the solubility at the surface of the API, the driving force for permeation is the concentration of the API already dissolved in the intestinal lumen. Although the upper limit of the luminal concentration is the solubility of the API, luminal concentrations may be much lower if the permeability is high or if the applied dose does not saturate the luminal fluids. The rDCS authors addressed these considerations by highlighting that useful risk classifications can only be derived when k<sub>diss</sub> &gt;&gt; k<sub>perm</sub> or k<sub>diss</sub> &lt;&lt; k<sub>perm</sub> [<xref rid="B10-pharmaceutics-15-01909" ref-type="bibr">10</xref>]. Another limitation of the rate constant comparison is that k<sub>diss</sub> must be calculated with a specific particle size, which was set to r = 100 &#181;m [<xref rid="B10-pharmaceutics-15-01909" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-15-01909" ref-type="bibr">11</xref>].</p><p>In the present work, the estimated maximal rates of dissolution and permeation rather than their rate constants are compared. This approach offers the advantage of taking the main driving forces for dissolution and permeation into account while delivering a specific target particle size. It thereby complements the dissolution/transit balance approach by relating r<sub>target</sub> values to permeability. The r<sub>target</sub> values can be interpreted as the particle size threshold above which dissolution rather than the permeation becomes limiting to oral absorption.</p></sec><sec id="sec5dot2-pharmaceutics-15-01909"><title>5.2. Use of Solubility and Intrinsic Dissolution Rate as Input for Target Particle Size Calculations </title><p>The DCS recommended an estimate of the intestinal solubility to calculate r<sub>target</sub> based on Dn. In the rDCS the IDR was added as a further possibility for calculating the dissolution rate constant. This work explored both input parameters. Comparison of the results obtained using C<sub>S</sub> and IDR can help to inform the formulator whether factors other than the solubility influence the dissolution rate, e.g., wettability of the surface or simultaneous reactions during diffusion across the ABL [<xref rid="B10-pharmaceutics-15-01909" ref-type="bibr">10</xref>,<xref rid="B43-pharmaceutics-15-01909" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-15-01909" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceutics-15-01909" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceutics-15-01909" ref-type="bibr">46</xref>,<xref rid="B47-pharmaceutics-15-01909" ref-type="bibr">47</xref>,<xref rid="B48-pharmaceutics-15-01909" ref-type="bibr">48</xref>,<xref rid="B49-pharmaceutics-15-01909" ref-type="bibr">49</xref>]. Possible reactions include acid-base reactions (ionization), partitioning into bile component micelles (or those generated by adding surfactant excipients), or complexation [<xref rid="B43-pharmaceutics-15-01909" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-15-01909" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceutics-15-01909" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceutics-15-01909" ref-type="bibr">46</xref>,<xref rid="B47-pharmaceutics-15-01909" ref-type="bibr">47</xref>,<xref rid="B48-pharmaceutics-15-01909" ref-type="bibr">48</xref>,<xref rid="B49-pharmaceutics-15-01909" ref-type="bibr">49</xref>,<xref rid="B50-pharmaceutics-15-01909" ref-type="bibr">50</xref>]. For instance, Teleki et al. reported that IDR values were not solely determined by solubility and its pH dependence because several APIs with similar solubilities in FaSSIF V1 and fed state simulated intestinal fluid (FeSSIF) showed notable differences in their IDRs in the same media [<xref rid="B46-pharmaceutics-15-01909" ref-type="bibr">46</xref>]. </p><p>We note that, for poorly soluble weak bases, the solubility and IDR determined under intestinal conditions represent a &#8220;worst case&#8221; (most conservative) scenario, because they assume that there is no supersaturation in the intestine [<xref rid="B9-pharmaceutics-15-01909" ref-type="bibr">9</xref>]. For weak bases, calculating the r<sub>target</sub> values using the gastric solubility (or IDR) as input (&#8220;best case&#8221; scenario) or supersaturation data from two-stage or transfer model experiments, as suggested in the rDCS customized investigations, may help to clarify the potential in vivo performance of the API, and set formulation goals.</p></sec><sec id="sec5dot3-pharmaceutics-15-01909"><title>5.3. Selection of the Relevant Aqueous Boundary Layer Assumption </title><p>Assumptions about the ABL thickness (h<sub>particle</sub>) are required in all previously described approaches. In the DCS and rDCS approaches, h<sub>particle</sub> was set equal to the particle radius [<xref rid="B9-pharmaceutics-15-01909" ref-type="bibr">9</xref>]. As described earlier, this assumption is generally thought to be most relevant for particle radii &lt; 30 &#181;m [<xref rid="B19-pharmaceutics-15-01909" ref-type="bibr">19</xref>]. For particle sizes exceeding 30 &#181;m, h<sub>particle</sub> tends to approach a constant value and can be set to, e.g., 30 &#181;m or, alternatively, h<sub>disk</sub>. In the present work, the choice of h<sub>particle</sub> was therefore addressed by implementing a bracketing approach using multiple equations that represent &#8220;best case&#8221; and &#8220;worst case&#8221; scenarios. The r<sub>target</sub> values can be calculated under the following h assumptions: (i) h<sub>particle</sub> = r<sub>0</sub>, (ii) h<sub>particle</sub> = 30 &#181;m, and (iii) h<sub>particle</sub> = h<sub>disk</sub>. It is recommended to calculate the r<sub>target</sub> values using all three assumptions, and if the target value calculated using h<sub>particle</sub> = r<sub>0</sub> is greater than 30 &#181;m, put more weight on the values calculated using the 30 &#181;m or h<sub>disk</sub> assumptions. </p></sec><sec id="sec5dot4-pharmaceutics-15-01909"><title>5.4. Case Studies</title><p>Voriconazole, lemborexant and istradefylline were used as model drugs for implementation of the various approaches to calculating r<sub>target</sub>, since they represent compounds with widely different chemical structures, solubilities, and IDRs, which are reflected in their respective rDCS classifications and r<sub>target</sub> estimations (<xref rid="pharmaceutics-15-01909-t005" ref-type="table">Table 5</xref> and <xref rid="pharmaceutics-15-01909-t008" ref-type="table">Table 8</xref>). </p><sec id="sec5dot4dot1-pharmaceutics-15-01909"><title>5.4.1. Voriconazole</title><p>Voriconazole is a weakly basic and moderately lipophilic API with a pK<sub>a</sub> of 1.76 [<xref rid="B32-pharmaceutics-15-01909" ref-type="bibr">32</xref>] and a logD<sub>pH7.4</sub> of 1.66 &#177; 0.03. It is predominantly unionized under physiological conditions in the small intestine (pH 6.5) and has a measured solubility in FaSSIF V1 of 827 &#177; 6 &#181;g/mL. The measured disk IDR (84.8 &#177; 1.4 &#181;g/min/cm<sup>2</sup>) correlated well with the theoretical disk IDR (based on the Levich equation with C<sub>S</sub> as input) of 87.0 &#177; 0.6 &#181;g/min/cm<sup>2</sup> [<xref rid="B23-pharmaceutics-15-01909" ref-type="bibr">23</xref>]. This suggests that the disk dissolution rate was not impacted by factors such as wetting or reactions in the ABL. As a result, r<sub>target</sub> estimates calculated from C<sub>S</sub> and IDR were not significantly different (<italic toggle="yes">p</italic> = 0.659). The human P<sub>eff</sub> of 4.30 &#215; 10<sup>&#8722;6</sup> cm/s, estimated from in vitro Caco-2 permeability data, suggests high permeability of the compound (<xref rid="pharmaceutics-15-01909-t006" ref-type="table">Table 6</xref>). </p><p>Doses up to 414 mg (D/S ratio = 500 mL) were classified as rDCS class I, while higher doses up to the SLAD of 1810 mg were classified as class IIa. In healthy volunteers, typical therapeutic doses of voriconazole, such as 200 mg (oral maintenance dose) or 400 mg (oral loading dose), are well absorbed with bioavailabilities of 85% or higher [<xref rid="B29-pharmaceutics-15-01909" ref-type="bibr">29</xref>,<xref rid="B51-pharmaceutics-15-01909" ref-type="bibr">51</xref>]. This is in line with the low risk predicted by the rDCS standard investigations (rDCS class I<sub>200mg</sub> and I<sub>400mg</sub>). After administration of high single oral doses of 800, 1200 and 1600 mg, voriconazole exposure in terms of AUC and C<sub>max</sub> increased proportionally with dose, in line with the calculated SLAD [<xref rid="B52-pharmaceutics-15-01909" ref-type="bibr">52</xref>]. The low developability risk for voriconazole predicted by the rDCS standard investigations was thus in line with the clinical findings. </p><p>Regarding target particle size, the dissolution/transit balance approach with h<sub>particle</sub> = r<sub>0</sub> and C<sub>S</sub> as input (Equation (7)) resulted in a r<sub>target</sub> value of 124 &#181;m. As mentioned above, when target particle size values based on h<sub>particle</sub> = r<sub>0</sub> exceed 30 &#181;m, this approach might be too conservative. The other h<sub>particle</sub> assumptions (h<sub>particle</sub> = 30 &#181;m or h<sub>particle</sub> = h<sub>disk</sub> = 42.5 &#181;m) resulted in larger r<sub>target</sub> estimates of 516 &#181;m and 364 &#181;m, respectively. In summary, the dissolution/transit balance approach indicated that there is no need for extensive particle size reduction when formulating a conventional oral dosage form containing voriconazole. The dissolution/permeation balance approach with C<sub>S</sub> as input led to a similar conclusion (r<sub>target</sub> = 118 &#181;m with h<sub>particle</sub> = 30 &#181;m and r<sub>target</sub> = 83.3 &#181;m with h<sub>particle</sub> = h<sub>disk</sub> = 42.5 &#181;m), although the particle size limit was lower across all ABL assumptions. Voriconazole is an rDCS class I drug, i.e., it is highly permeable and has a low D/S ratio at the recommended dose levels, so that sink conditions will likely be maintained during in vivo dissolution. Therefore, the dissolution/transit balance approach is expected to yield the most relevant values.</p><p>Relevant information on voriconazole particle size in products is scarce in the open literature. The EMA European Public Assessment report (EPAR) for the originator VFEND<sup>&#174;</sup> stated that batches with a wide variety of particle size distributions were clinically acceptable [<xref rid="B53-pharmaceutics-15-01909" ref-type="bibr">53</xref>]. Generic film-coated tablets manufactured from drug substance with D<sub>90</sub> &#8804; 90 &#956;m (Vorcon, Southern Cross Pharma Pty Ltd., Hawthorn, Australia) were bioequivalent to the innovator VFEND<sup>&#174;</sup> (200 mg) and both Vorcon and VFEND<sup>&#174;</sup> tablets dissolved to an extent of &#8805;85% within 15 min in &#8220;media of various pH&#8221; [<xref rid="B54-pharmaceutics-15-01909" ref-type="bibr">54</xref>]. The in vitro dissolution profiles of tablets containing unmicronised API (particle size not disclosed) were reported to be noticeably slower [<xref rid="B54-pharmaceutics-15-01909" ref-type="bibr">54</xref>]. As the particle size specification for the Vorcon product is below the estimated r<sub>target</sub> values discussed above, it falls well within a &#8220;safe space&#8221; in which dissolution rate limitations to oral absorption are very unlikely to occur.</p></sec><sec id="sec5dot4dot2-pharmaceutics-15-01909"><title>5.4.2. Lemborexant</title><p>Lemborexant is a lipophilic weak base with a pK<sub>a</sub> of 2.18 &#177; 0.05 and a logD<sub>pH7.4</sub> of 3.04 &#177; 0.05. Under small-intestinal pH conditions lemborexant is present in its neutral form and exhibits poor solubility (23.3 &#177; 0.1 &#181;g/mL). The measured disk IDR in FaSSIF V1 (1.99 &#177; 0.09 &#181;g/min/cm<sup>2</sup>) was slightly lower than the theoretical IDR (2.24 &#177; 0.01 &#181;g/min/cm<sup>2</sup>) estimated from C<sub>S</sub> (<italic toggle="yes">p</italic> = 0.014). Although statistically significant, the difference in r<sub>target</sub> values calculated from C<sub>S</sub> or IDR did not seem to be of practical relevance (<xref rid="pharmaceutics-15-01909-t008" ref-type="table">Table 8</xref>). Lemborexant was considered highly permeable with a predicted human P<sub>eff</sub> of 4.20 &#215; 10<sup>&#8722;6</sup> cm/s. The rDCS classified lemborexant as follows: rDCS class I<sub>5mg</sub>, IIa/b<sub>50mg</sub> and IIb<sub>500mg</sub> with an SLAD of 49.6 mg.</p><p>Tablets for oral use containing 2.5, 5, or 10 mg of lemborexant are commercially available [<xref rid="B55-pharmaceutics-15-01909" ref-type="bibr">55</xref>]. In line with its classification as rDCS class I<sub>1-10mg</sub>, single oral lemborexant doses ranging from 1 to 10 mg were absorbed rapidly in healthy adults with a median t<sub>max</sub> of approximately 1 h [<xref rid="B56-pharmaceutics-15-01909" ref-type="bibr">56</xref>,<xref rid="B57-pharmaceutics-15-01909" ref-type="bibr">57</xref>]. In a human mass-balance study only about 13% of a 10 mg [<sup>14</sup>C]lemborexant dose was recovered unchanged in feces, corresponding to a fraction of oral dose absorbed (Fa) of 87% [<xref rid="B33-pharmaceutics-15-01909" ref-type="bibr">33</xref>,<xref rid="B57-pharmaceutics-15-01909" ref-type="bibr">57</xref>,<xref rid="B58-pharmaceutics-15-01909" ref-type="bibr">58</xref>]. Lemborexant exposure was shown to increase in a dose-proportional manner in the range 1 to 10 mg [<xref rid="B56-pharmaceutics-15-01909" ref-type="bibr">56</xref>].</p><p>The dissolution rate analysis for the 10 mg dose resulted in particle size estimates &lt;30 &#181;m (<xref rid="pharmaceutics-15-01909-t008" ref-type="table">Table 8</xref>), so h<sub>particle</sub> = r<sub>0</sub> likely represents the most relevant assumption of ABL thickness. Values using h<sub>particle</sub> = 30 &#181;m or h<sub>particle</sub> = h<sub>disk</sub> = 40.7 &#181;m led to lower r<sub>target</sub> values since in these approaches, h<sub>particle</sub> was larger than the calculated particle radius. In summary, the dissolution/transit balance approach predicted particles with a radius of &#8804;20 &#181;m to dissolve within the intestinal transit time under sink conditions and the dissolution/permeation balance approach predicted a particle size cut-off for dissolution rate limitations of approximately 10 &#181;m. Like voriconazole, lemborexant is an rDCS Class I drug at the commercially available dose levels and hence in vivo dissolution under sink conditions can be expected. Therefore, r<sub>target</sub> values estimated using the dissolution/transit balance approach are likely to be more relevant than values derived from the dissolution/permeation balance approach. </p><p>Particle size specifications of the marketed product (DAYVIGO<sup>&#174;</sup>) have not been disclosed. However, dissolution of lemborexant tablets containing 2.5 to 10 mg API has been reported in the patent literature [<xref rid="B59-pharmaceutics-15-01909" ref-type="bibr">59</xref>]. The dissolution curves for 10 mg lemborexant tablets with different D<sub>90</sub> values are presented in <xref rid="pharmaceutics-15-01909-f005" ref-type="fig">Figure 5</xref>. Lemborexant dissolution was reported to be fast and not affected by particle size in the range of 20 to 98 &#181;m (D<sub>90</sub>) in 0.1 M hydrochloric acid [<xref rid="B59-pharmaceutics-15-01909" ref-type="bibr">59</xref>], where the solubility of lemborexant is considerably enhanced by ionization (1.6 mg/mL at pH 1.0) [<xref rid="B39-pharmaceutics-15-01909" ref-type="bibr">39</xref>]. Dissolution was slower and substantially affected by particle size when tested at pH 6.8, in line with the target particle sizes of &#8804;20 &#181;m calculated according to the equations using the dissolution/transit balance approach (<xref rid="pharmaceutics-15-01909-t008" ref-type="table">Table 8</xref>) [<xref rid="B59-pharmaceutics-15-01909" ref-type="bibr">59</xref>]. </p></sec><sec id="sec5dot4dot3-pharmaceutics-15-01909"><title>5.4.3. Istradefylline </title><p>The xanthine derivative istradefylline is a moderately lipophilic (logD<sub>pH7.4</sub> = 2.96 &#177; 0.03) and very weakly basic API (pK<sub>a</sub> = 0.78) [<xref rid="B31-pharmaceutics-15-01909" ref-type="bibr">31</xref>,<xref rid="B34-pharmaceutics-15-01909" ref-type="bibr">34</xref>] exhibiting poor solubility in FaSSIF V1 (3.59 &#177; 0.05 &#181;g/mL). The IDR of istradefylline estimated from powder dissolution experiments in FaSSIF V1 (0.302 &#177; 0.010 &#181;g/min/cm<sup>2</sup>) was somewhat lower than the value estimated from its solubility (0.346 &#177; 0.005 &#181;g/min/cm<sup>2</sup>, <italic toggle="yes">p</italic> = 0.0009). As for lemborexant, the difference had no practical impact on the r<sub>target</sub> estimations (<xref rid="pharmaceutics-15-01909-t008" ref-type="table">Table 8</xref>). The very low solubility combined with the high estimated human P<sub>eff</sub> of 4.66 &#215; 10<sup>&#8722;6</sup> cm/s resulted in classification of istradefylline as rDCS class IIa<sub>5mg</sub>, IIb<sub>50mg</sub> and IIb<sub>500mg</sub> with an SLAD of 8.50 mg.</p><p>The rDCS and r<sub>target</sub> analyses indicated that the development of conventional oral istradefylline formulations at doses of around 10 mg or more would be associated with a high risk, much greater than for voriconazole or lemborexant. The classification as class IIb indicated that the solubility of the API poses a potential risk, and the r<sub>target</sub> estimations showed that dissolution rate can have an additional influence. It is noted that particle size estimates using the dissolution/transit balance approach tend to lose some relevance for rDCS class IIb drugs because sink conditions are likely not maintained during the intestinal transit (due to their high D/S ratios). However, the r<sub>target</sub> values calculated from the dissolution/permeation balance approach suggest that particle size reduction below approximately 12 &#181;m may help mitigate dissolution rate limitations.</p><p>Oral tablets containing istradefylline are marketed in Japan (20 mg) and the USA (20 and 40 mg) [<xref rid="B60-pharmaceutics-15-01909" ref-type="bibr">60</xref>,<xref rid="B61-pharmaceutics-15-01909" ref-type="bibr">61</xref>]. The 20 and 40 mg tablets are dose proportional [<xref rid="B34-pharmaceutics-15-01909" ref-type="bibr">34</xref>]. To the best of our knowledge, clinical studies investigating the absolute oral bioavailability of istradefylline formulations have not been conducted because of the compound&#8217;s poor aqueous solubility, which has prevented the development of a suitable intravenous formulation for clinical use [<xref rid="B62-pharmaceutics-15-01909" ref-type="bibr">62</xref>]. However, after oral administration of a suspension containing 40 mg of [<sup>14</sup>C]istradefylline to healthy male subjects, 38.9 &#177; 10.7% and 48.0 &#177; 13.4% of the administered radioactivity were recovered in urine and feces, respectively [<xref rid="B63-pharmaceutics-15-01909" ref-type="bibr">63</xref>]. The significant amount of drug in feces suggests that istradefylline absorption may be incomplete, in line with its classification as an rDCS class IIb API.</p><p>Particle size reduction of istradefylline to particle radii &#8804;12.6 &#181;m (h<sub>particle</sub> = r<sub>0</sub>) was expected to reduce the risk of dissolution rate limitations at the 20 mg dose level. However, particle size reduction alone is not expected to resolve the solubility issue, which should be addressed through other formulation approaches. According to the patent literature, crystals of istradefylline exhibit low aqueous solubility and are needle-like with a width of several &#181;m and a length of several hundred &#181;m (<xref rid="app1-pharmaceutics-15-01909" ref-type="app">Supplementary Materials</xref>) [<xref rid="B64-pharmaceutics-15-01909" ref-type="bibr">64</xref>]. Particle size reduction of istradefylline crystals was performed, resulting in microcrystals with an average particle size of 0.5 to 20 &#181;m and an increased amorphous content of up to 80% [<xref rid="B64-pharmaceutics-15-01909" ref-type="bibr">64</xref>]. The reduction in particle size and generation of amorphous material resulted in a significant increase in the dissolution rate of the microcrystals in water [<xref rid="B64-pharmaceutics-15-01909" ref-type="bibr">64</xref>]. Although there are no supporting human data available, administration of a suspension of the microcrystals resulted in an approximately three-fold increase in both AUC and C<sub>max</sub> in rats compared to the unmilled material (<xref rid="pharmaceutics-15-01909-f006" ref-type="fig">Figure 6</xref>) [<xref rid="B64-pharmaceutics-15-01909" ref-type="bibr">64</xref>]. This example supports the use of the rDCS and r<sub>target</sub> calculations to estimate the risks associated with istradefylline formulations and guide the efforts necessary to guarantee sufficient bioavailability by combining the strategies of particle size reduction to increase dissolution rate and amorphization to increase solubility.</p></sec></sec></sec><sec sec-type="conclusions" id="sec6-pharmaceutics-15-01909"><title>6. Conclusions</title><p>This work introduces new, analytically solvable equations for estimating API target particle size based on in vitro tests that are commonly used in early oral formulation development (solubility, permeability, IDR). An Excel spreadsheet for automated calculation of all r<sub>target</sub> values is provided as <xref rid="app1-pharmaceutics-15-01909" ref-type="app">Supplementary Materials</xref> for easy implementation of the equations.</p><p>As demonstrated with the three case examples presented, this rDCS-based approach can be used to support initial particle size specifications, suggest whether particle size reduction may be an appropriate formulation strategy and determine whether a formulation which enhances solubility is required. </p><p>Further benefits of this approach are expected at various stages of oral drug development, including (i) selection of a suitable particle size for preclinical toxicological studies, thus reducing the use of animals in this type of study as well as in formulation assessment, (ii) a priori selection of a suitable particle size for first-in-human studies and thus reduction or even elimination of the need for pharmacokinetic studies in large animal species such as dogs and swine, and (iii) rational assessment of the absorption risk linked to API particle size, which can then trigger the investigation of clinically relevant specifications at the time of filing.</p><p>Application of the r<sub>target</sub> equations to more drugs with diverse structures and properties will assist in establishing them as a practical substitute for trial-and-error approaches for determining drug particle size in preclinical toxicity studies as well as reducing the use of animals and time required for formulation development.</p></sec></body><back><ack><title>Acknowledgments</title><p>The pK<sub>a</sub> and log<sub>DpH7.4</sub> studies were performed at Pion Inc (UK) Ltd. (Forest Row, UK). The Caco-2 permeability studies were performed at Cyprotex Discovery Ltd. (Macclesfield, UK) with the kind support of Kevin Coe from Janssen Pharmaceutica (La Jolla, CA, USA).</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceutics-15-01909"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/pharmaceutics15071909/s1">https://www.mdpi.com/article/10.3390/pharmaceutics15071909/s1</uri>, File S1: Projection of target drug particle size; File S2: Template for Automated r<sub>target</sub> Calculations. References [<xref rid="B3-pharmaceutics-15-01909" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceutics-15-01909" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceutics-15-01909" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceutics-15-01909" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceutics-15-01909" ref-type="bibr">7</xref>,<xref rid="B10-pharmaceutics-15-01909" ref-type="bibr">10</xref>,<xref rid="B12-pharmaceutics-15-01909" ref-type="bibr">12</xref>,<xref rid="B16-pharmaceutics-15-01909" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceutics-15-01909" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-15-01909" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-15-01909" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceutics-15-01909" ref-type="bibr">20</xref>,<xref rid="B23-pharmaceutics-15-01909" ref-type="bibr">23</xref>,<xref rid="B25-pharmaceutics-15-01909" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-15-01909" ref-type="bibr">26</xref>,<xref rid="B31-pharmaceutics-15-01909" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-15-01909" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-15-01909" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceutics-15-01909" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceutics-15-01909" ref-type="bibr">35</xref>,<xref rid="B41-pharmaceutics-15-01909" ref-type="bibr">41</xref>,<xref rid="B65-pharmaceutics-15-01909" ref-type="bibr">65</xref>,<xref rid="B66-pharmaceutics-15-01909" ref-type="bibr">66</xref>] are cited in the Supplementary Materials.</p><supplementary-material id="pharmaceutics-15-01909-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceutics-15-01909-s001.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, K.B., E.H., R.H., K.S. and J.D.; methodology, K.B., E.H., R.H., K.S. and J.D.; validation, K.B., E.H., R.H., K.S. and J.D.; formal analysis, K.B., E.H., R.H., K.S. and J.D.; investigation, K.B. (equations and calculations);; data curation, K.B. and J.D.; writing&#8212;original draft preparation, K.B. and J.D.; writing&#8212;review and editing, E.H., R.H., K.S. and J.D.; visualization, K.B., E.H., R.H. and J.D.; supervision, E.H., R.H., K.S. and J.D.; project administration, J.D. (Fraunhofer), E.H. (Janssen); funding acquisition, E.H., R.H. and J.D. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>All data is reported in the manuscript and in the <xref rid="app1-pharmaceutics-15-01909" ref-type="app">Supplementary Materials</xref>.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-15-01909"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amidon</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Lennern&#228;s</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Crison</surname><given-names>J.R.</given-names></name></person-group><article-title>A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability</article-title><source>Pharm. Res.</source><year>1995</year><volume>12</volume><fpage>413</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1023/A:1016212804288</pub-id><pub-id pub-id-type="pmid">7617530</pub-id></element-citation></ref><ref id="B2-pharmaceutics-15-01909"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sugano</surname><given-names>K.</given-names></name><name name-style="western"><surname>Terada</surname><given-names>K.</given-names></name></person-group><article-title>Rate- and Extent-Limiting Factors of Oral Drug Absorption: Theory and Applications</article-title><source>J. Pharm. Sci.</source><year>2015</year><volume>104</volume><fpage>2777</fpage><lpage>2788</lpage><pub-id pub-id-type="doi">10.1002/jps.24391</pub-id><pub-id pub-id-type="pmid">25712830</pub-id></element-citation></ref><ref id="B3-pharmaceutics-15-01909"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Sugano</surname><given-names>K.</given-names></name></person-group><source>Biopharmaceutics Modelling and Simulations: Theory, Practice, Methods, and Applications</source><edition>1st ed.</edition><publisher-name>John Wiley &amp; Sons, Inc.</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2012</year><fpage>1</fpage><lpage>325</lpage></element-citation></ref><ref id="B4-pharmaceutics-15-01909"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noyes</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Whitney</surname><given-names>W.R.</given-names></name></person-group><article-title>The rate of solution of solid substances in their own solutions</article-title><source>J. Am. Chem. Soc.</source><year>1897</year><volume>19</volume><fpage>930</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1021/ja02086a003</pub-id></element-citation></ref><ref id="B5-pharmaceutics-15-01909"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nernst</surname><given-names>W.</given-names></name></person-group><article-title>Theorie der Reaktionsgeschwindigkeit in heterogenen Systemen</article-title><source>Z. Phys. Chem.</source><year>1904</year><volume>47</volume><fpage>52</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1515/zpch-1904-4704</pub-id></element-citation></ref><ref id="B6-pharmaceutics-15-01909"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brunner</surname><given-names>E.</given-names></name></person-group><article-title>Reaktionsgeschwindigkeit in heterogenen Systemen</article-title><source>Z. Phys. Chem.</source><year>1904</year><volume>43</volume><fpage>56</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1515/zpch-1904-4705</pub-id></element-citation></ref><ref id="B7-pharmaceutics-15-01909"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dokoumetzidis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Macheras</surname><given-names>P.</given-names></name></person-group><article-title>A century of dissolution research: From Noyes and Whitney to the Biopharmaceutics Classification System</article-title><source>Int. J. Pharm.</source><year>2006</year><volume>321</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2006.07.011</pub-id><pub-id pub-id-type="pmid">16920290</pub-id></element-citation></ref><ref id="B8-pharmaceutics-15-01909"><label>8.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>ICH Harmonised Tripartite Guideline</collab></person-group><article-title>Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. Q6A</article-title><year>1999</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ich.org/page/quality-guidelines" ext-link-type="uri">https://www.ich.org/page/quality-guidelines</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-07-04">(accessed on 1 July 2023)</date-in-citation></element-citation></ref><ref id="B9-pharmaceutics-15-01909"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butler</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Dressman</surname><given-names>J.B.</given-names></name></person-group><article-title>The developability classification system: Application of biopharmaceutics concepts to formulation development</article-title><source>J. Pharm. Sci.</source><year>2010</year><volume>99</volume><fpage>4940</fpage><lpage>4954</lpage><pub-id pub-id-type="doi">10.1002/jps.22217</pub-id><pub-id pub-id-type="pmid">20821390</pub-id></element-citation></ref><ref id="B10-pharmaceutics-15-01909"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenberger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dressman</surname><given-names>J.</given-names></name></person-group><article-title>A Refined Developability Classification System</article-title><source>J. Pharm. Sci.</source><year>2018</year><volume>107</volume><fpage>2020</fpage><lpage>2032</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2018.03.030</pub-id><pub-id pub-id-type="pmid">29665381</pub-id></element-citation></ref><ref id="B11-pharmaceutics-15-01909"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenberger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Muenster</surname><given-names>U.</given-names></name><name name-style="western"><surname>Dressman</surname><given-names>J.</given-names></name></person-group><article-title>Application of a Refined Developability Classification System</article-title><source>J. Pharm. Sci.</source><year>2019</year><volume>108</volume><fpage>1090</fpage><lpage>1100</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2018.10.044</pub-id><pub-id pub-id-type="pmid">30389565</pub-id></element-citation></ref><ref id="B12-pharmaceutics-15-01909"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Curl</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Amidon</surname><given-names>G.L.</given-names></name></person-group><article-title>Estimating the Fraction Dose Absorbed from Suspensions of Poorly Soluble Compounds in Humans: A Mathematical Model</article-title><source>Pharm. Res.</source><year>1993</year><volume>10</volume><fpage>264</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1023/A:1018947113238</pub-id><pub-id pub-id-type="pmid">8456075</pub-id></element-citation></ref><ref id="B13-pharmaceutics-15-01909"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sj&#246;gren</surname><given-names>E.</given-names></name><name name-style="western"><surname>Abrahamsson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Augustijns</surname><given-names>P.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bolger</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Brewster</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brouwers</surname><given-names>J.</given-names></name><name name-style="western"><surname>Flanagan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Harwood</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heinen</surname><given-names>C.</given-names></name><etal/></person-group><article-title>In vivo methods for drug absorption&#8212;Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects</article-title><source>Eur. J. Pharm. Sci.</source><year>2014</year><volume>57</volume><fpage>99</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2014.02.010</pub-id><pub-id pub-id-type="pmid">24637348</pub-id></element-citation></ref><ref id="B14-pharmaceutics-15-01909"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>James</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>Hume</surname><given-names>R.</given-names></name></person-group><article-title>Action of metoclopramide on gastric emptying and small bowel transit time</article-title><source>Gut</source><year>1968</year><volume>9</volume><fpage>203</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1136/gut.9.2.203</pub-id><pub-id pub-id-type="pmid">5655030</pub-id><pub-id pub-id-type="pmcid">PMC1552556</pub-id></element-citation></ref><ref id="B15-pharmaceutics-15-01909"><label>15.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>ICH Harmonised Guideline</collab></person-group><article-title>Biopharmaceutics Classification System-Based Biowaivers. M9</article-title><year>2019</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ich.org/page/multidisciplinary-guidelines" ext-link-type="uri">https://www.ich.org/page/multidisciplinary-guidelines</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-07-04">(accessed on 1 July 2023)</date-in-citation></element-citation></ref><ref id="B16-pharmaceutics-15-01909"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dressman</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Fleisher</surname><given-names>D.</given-names></name></person-group><article-title>Mixing-tank model for predicting dissolution rate control or oral absorption</article-title><source>J. Pharm. Sci.</source><year>1986</year><volume>75</volume><fpage>109</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1002/jps.2600750202</pub-id><pub-id pub-id-type="pmid">3958917</pub-id></element-citation></ref><ref id="B17-pharmaceutics-15-01909"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Higuchi</surname><given-names>W.I.</given-names></name><name name-style="western"><surname>Hiestand</surname><given-names>E.N.</given-names></name></person-group><article-title>Dissolution rates of finely divided drug powders I. Effect of a distribution of particle sizes in a diffusion-controlled process</article-title><source>J. Pharm. Sci.</source><year>1963</year><volume>52</volume><fpage>67</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1002/jps.2600520114</pub-id><pub-id pub-id-type="pmid">13954443</pub-id></element-citation></ref><ref id="B18-pharmaceutics-15-01909"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hintz</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>K.C.</given-names></name></person-group><article-title>The effect of particle size distribution on dissolution rate and oral absorption</article-title><source>Int. J. Pharm.</source><year>1989</year><volume>51</volume><fpage>9</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/0378-5173(89)90069-0</pub-id></element-citation></ref><ref id="B19-pharmaceutics-15-01909"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okazaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mano</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sugano</surname><given-names>K.</given-names></name></person-group><article-title>Theoretical dissolution model of poly-disperse drug particles in biorelevant media</article-title><source>J. Pharm. Sci.</source><year>2008</year><volume>97</volume><fpage>1843</fpage><lpage>1852</lpage><pub-id pub-id-type="doi">10.1002/jps.21070</pub-id><pub-id pub-id-type="pmid">17828749</pub-id></element-citation></ref><ref id="B20-pharmaceutics-15-01909"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arav</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bercovier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Parnas</surname><given-names>H.</given-names></name></person-group><article-title>Selecting the particle size distribution for drugs with low water solubility&#8212;Mathematical model</article-title><source>Drug. Dev. Ind. Pharm.</source><year>2012</year><volume>38</volume><fpage>940</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.3109/03639045.2011.634808</pub-id><pub-id pub-id-type="pmid">22320660</pub-id></element-citation></ref><ref id="B21-pharmaceutics-15-01909"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harriott</surname><given-names>P.</given-names></name></person-group><article-title>Mass transfer to particles: Part I. Suspended in agitated tanks</article-title><source>AIChE J.</source><year>1962</year><volume>8</volume><fpage>93</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1002/aic.690080122</pub-id></element-citation></ref><ref id="B22-pharmaceutics-15-01909"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsinman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Avdeef</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tsinman</surname><given-names>O.</given-names></name><name name-style="western"><surname>Voloboy</surname><given-names>D.</given-names></name></person-group><article-title>Powder Dissolution Method for Estimating Rotating Disk Intrinsic Dissolution Rates of Low Solubility Drugs</article-title><source>Pharm. Res.</source><year>2009</year><volume>26</volume><fpage>2093</fpage><lpage>2100</lpage><pub-id pub-id-type="doi">10.1007/s11095-009-9921-3</pub-id><pub-id pub-id-type="pmid">19543816</pub-id></element-citation></ref><ref id="B23-pharmaceutics-15-01909"><label>23.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Levich</surname><given-names>V.G.</given-names></name></person-group><source>Physicochemical Hydrodynamics</source><edition>2nd ed.</edition><publisher-name>Prentice Hall, Inc.</publisher-name><publisher-loc>Englewood Cliffs, NJ, USA</publisher-loc><year>1962</year><fpage>39</fpage><lpage>72</lpage></element-citation></ref><ref id="B24-pharmaceutics-15-01909"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name></person-group><article-title>Investigation of Photostability of Istradefylline Aqueous Solution</article-title><source>ChemistrySelect</source><year>2020</year><volume>5</volume><fpage>2337</fpage><lpage>2341</lpage><pub-id pub-id-type="doi">10.1002/slct.201904148</pub-id></element-citation></ref><ref id="B25-pharmaceutics-15-01909"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hubatsch</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ragnarsson</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Artursson</surname><given-names>P.</given-names></name></person-group><article-title>Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers</article-title><source>Nat. Protoc.</source><year>2007</year><volume>2</volume><fpage>2111</fpage><lpage>2119</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.303</pub-id><pub-id pub-id-type="pmid">17853866</pub-id></element-citation></ref><ref id="B26-pharmaceutics-15-01909"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lennern&#228;s</surname><given-names>H.</given-names></name><name name-style="western"><surname>Welage</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Barnett</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Landowski</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Foster</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fleisher</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.</given-names></name><name name-style="western"><surname>Amidon</surname><given-names>G.L.</given-names></name></person-group><article-title>Comparison of Human Duodenum and Caco-2 Gene Expression Profiles for 12,000 Gene Sequences Tags and Correlation with Permeability of 26 Drugs</article-title><source>Pharm. Res.</source><year>2002</year><volume>19</volume><fpage>1400</fpage><lpage>1416</lpage><pub-id pub-id-type="doi">10.1023/A:1020483911355</pub-id><pub-id pub-id-type="pmid">12425456</pub-id></element-citation></ref><ref id="B27-pharmaceutics-15-01909"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avdeef</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tsinman</surname><given-names>O.</given-names></name></person-group><article-title>Miniaturized Rotating Disk Intrinsic Dissolution Rate Measurement: Effects of Buffer Capacity in Comparisons to Traditional Wood&#8217;s Apparatus</article-title><source>Pharm. Res.</source><year>2008</year><volume>25</volume><fpage>2613</fpage><lpage>2627</lpage><pub-id pub-id-type="doi">10.1007/s11095-008-9679-z</pub-id><pub-id pub-id-type="pmid">18648912</pub-id></element-citation></ref><ref id="B28-pharmaceutics-15-01909"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersson</surname><given-names>S.B.E.</given-names></name><name name-style="western"><surname>Alvebratt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bevernage</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bonneau</surname><given-names>D.</given-names></name><name name-style="western"><surname>da Costa Mathews</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dattani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Edueng</surname><given-names>K.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Holm</surname><given-names>R.</given-names></name><name name-style="western"><surname>Madsen</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Interlaboratory Validation of Small-Scale Solubility and Dissolution Measurements of Poorly Water-Soluble Drugs</article-title><source>J. Pharm. Sci.</source><year>2016</year><volume>105</volume><fpage>2864</fpage><lpage>2872</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2016.03.010</pub-id><pub-id pub-id-type="pmid">27112289</pub-id></element-citation></ref><ref id="B29-pharmaceutics-15-01909"><label>29.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Pfizer Inc</collab></person-group><source>Highlights of Prescribing Information, VFEND&#174; (Voriconazole) Tablets, for Oral Use</source><publisher-name>Pfizer Inc.</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2022</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pfizermedicalinformation.com/en-us/vfend" ext-link-type="uri">https://www.pfizermedicalinformation.com/en-us/vfend</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-07-05">(accessed on 1 July 2023)</date-in-citation></element-citation></ref><ref id="B30-pharmaceutics-15-01909"><label>30.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Eisai Inc</collab></person-group><source>Highlights of Prescribing Information, DAYVIGO&#174; (Lemborexant) Tablets, for Oral Use</source><publisher-name>Eisai Inc.</publisher-name><publisher-loc>Nutley, NJ, USA</publisher-loc><year>2022</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dayvigo.com/" ext-link-type="uri">https://www.dayvigo.com/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-07-05">(accessed on 1 July 2023)</date-in-citation></element-citation></ref><ref id="B31-pharmaceutics-15-01909"><label>31.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Kyowa Kirin Inc</collab></person-group><source>Highlights of Prescribing information, NOURIANZ&#174; (Istradefylline) Tablets, for Oral Use</source><publisher-name>Kyowa Kirin Inc.</publisher-name><publisher-loc>Bedminster, NJ, USA</publisher-loc><year>2020</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nourianzhcp.com/" ext-link-type="uri">https://www.nourianzhcp.com/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-07-05">(accessed on 1 July 2023)</date-in-citation></element-citation></ref><ref id="B32-pharmaceutics-15-01909"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Damle</surname><given-names>B.</given-names></name><name name-style="western"><surname>Varma</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>N.</given-names></name></person-group><article-title>Pharmacokinetics of Voriconazole Administered Concomitantly with Fluconazole and Population-Based Simulation for Sequential Use</article-title><source>Antimicrob. Agents Chemother.</source><year>2011</year><volume>55</volume><fpage>5172</fpage><lpage>5177</lpage><pub-id pub-id-type="doi">10.1128/AAC.00423-11</pub-id><pub-id pub-id-type="pmid">21876043</pub-id><pub-id pub-id-type="pmcid">PMC3195022</pub-id></element-citation></ref><ref id="B33-pharmaceutics-15-01909"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ueno</surname><given-names>T.</given-names></name><name name-style="western"><surname>Miyajima</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Landry</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lalovic</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schuck</surname><given-names>E.</given-names></name></person-group><article-title>Physiologically-based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors</article-title><source>CPT Pharmacomet. Syst. Pharmacol.</source><year>2021</year><volume>10</volume><fpage>455</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1002/psp4.12606</pub-id><pub-id pub-id-type="pmid">33704920</pub-id><pub-id pub-id-type="pmcid">PMC8129715</pub-id></element-citation></ref><ref id="B34-pharmaceutics-15-01909"><label>34.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Food and Drug Administration</collab></person-group><source>Product Quality Review(s), Nourianz&#174; (Istradefylline) Tablets. Application Number: 022075Orig1s000</source><publisher-name>U.S. Food and Drug Administration</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2019</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022075Orig1s000TOC.cfm" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022075Orig1s000TOC.cfm</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-07-05">(accessed on 1 July 2023)</date-in-citation></element-citation></ref><ref id="B35-pharmaceutics-15-01909"><label>35.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name name-style="western"><surname>Sundaram</surname><given-names>V.</given-names></name><name name-style="western"><surname>Uppala</surname><given-names>V.B.R.U.</given-names></name><name name-style="western"><surname>Akundi</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Muvva</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chitta</surname><given-names>V.</given-names></name><name name-style="western"><surname>Donthula</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kharkar</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Devarakonda</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Peddireddy</surname><given-names>S.R.</given-names></name></person-group><article-title>Process for Preparing</article-title><source>Voriconazole. Patent</source><patent>WO 2006/065726 A2</patent><day>22</day><month>June</month><year>2006</year></element-citation></ref><ref id="B36-pharmaceutics-15-01909"><label>36.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>Crystalline form of orexin receptor antagonist, processes for preparation thereof and use thereof</article-title><source>U.S. Patent</source><patent>2020/0190060 A1</patent><day>18</day><month>June</month><year>2020</year></element-citation></ref><ref id="B37-pharmaceutics-15-01909"><label>37.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name name-style="western"><surname>Bao</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.Q.</given-names></name></person-group><article-title>Polymorphs of</article-title><source>Istradefylline. Patent</source><patent>CN 104744464A</patent><day>1</day><month>July</month><year>2015</year></element-citation></ref><ref id="B38-pharmaceutics-15-01909"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>M.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Q.</given-names></name></person-group><article-title>Studies on the Crystal Forms of Istradefylline: Structure, Solubility, and Dissolution Profile</article-title><source>Crystals</source><year>2022</year><volume>12</volume><elocation-id>917</elocation-id><pub-id pub-id-type="doi">10.3390/cryst12070917</pub-id></element-citation></ref><ref id="B39-pharmaceutics-15-01909"><label>39.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Food and Drug Administration</collab></person-group><source>Product Quality Review(s). Lemborexant Tablets. Application Number: 212028Orig1s000</source><publisher-name>U.S. Food and Drug Administration</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2019</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000TOC.cfm" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000TOC.cfm</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-07-05">(accessed on 1 July 2023)</date-in-citation></element-citation></ref><ref id="B40-pharmaceutics-15-01909"><label>40.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>European Medicines Agency</collab></person-group><source>Voriconazole Accord: EPAR&#8212;Public assessment report.</source><publisher-name>European Medicines Agency</publisher-name><publisher-loc>London, UK</publisher-loc><year>2013</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ema.europa.eu/en/medicines/human/EPAR/voriconazole-accord" ext-link-type="uri">https://www.ema.europa.eu/en/medicines/human/EPAR/voriconazole-accord</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-07-05">(accessed on 1 July 2023)</date-in-citation></element-citation></ref><ref id="B41-pharmaceutics-15-01909"><label>41.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Food and Drug Administration</collab></person-group><source>In Vitro Metabolism and Transporter Mediated Drug-Drug Interaction Studies Guidance for Industry</source><publisher-name>U.S. Food and Drug Administration</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2017</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/media/108130/download" ext-link-type="uri">https://www.fda.gov/media/108130/download</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-07-05">(accessed on 1 July 2023)</date-in-citation></element-citation></ref><ref id="B42-pharmaceutics-15-01909"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Grady</surname><given-names>J.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Barry</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shanahan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Buckley</surname><given-names>M.</given-names></name></person-group><article-title>Defining gastrointestinal transit time using video capsule endoscopy: A study of healthy subjects</article-title><source>Endosc. Int. Open</source><year>2020</year><volume>8</volume><fpage>E396</fpage><lpage>E400</lpage><pub-id pub-id-type="doi">10.1055/a-1073-7653</pub-id><pub-id pub-id-type="pmid">32118112</pub-id><pub-id pub-id-type="pmcid">PMC7035031</pub-id></element-citation></ref><ref id="B43-pharmaceutics-15-01909"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mooney</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Mintun</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Himmelstein</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Stella</surname><given-names>V.J.</given-names></name></person-group><article-title>Dissolution kinetics of carboxylic acids I: Effect of pH under unbuffered conditions</article-title><source>J. Pharm. Sci.</source><year>1981</year><volume>70</volume><fpage>13</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1002/jps.2600700103</pub-id><pub-id pub-id-type="pmid">7229925</pub-id></element-citation></ref><ref id="B44-pharmaceutics-15-01909"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mooney</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Mintun</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Himmelstein</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Stella</surname><given-names>V.J.</given-names></name></person-group><article-title>Dissolution kinetics of carboxylic acids II: Effect of buffers</article-title><source>J. Pharm. Sci.</source><year>1981</year><volume>70</volume><fpage>22</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1002/jps.2600700104</pub-id><pub-id pub-id-type="pmid">7229926</pub-id></element-citation></ref><ref id="B45-pharmaceutics-15-01909"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McNamara</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Amidon</surname><given-names>G.L.</given-names></name></person-group><article-title>Dissolution of acidic and basic compounds from the rotating disk: Influence of convective diffusion and reaction</article-title><source>J. Pharm. Sci.</source><year>1986</year><volume>75</volume><fpage>858</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1002/jps.2600750907</pub-id><pub-id pub-id-type="pmid">3783452</pub-id></element-citation></ref><ref id="B46-pharmaceutics-15-01909"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teleki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nylander</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bergstr&#246;m</surname><given-names>C.A.S.</given-names></name></person-group><article-title>Intrinsic Dissolution Rate Profiling of Poorly Water-Soluble Compounds in Biorelevant Dissolution Media</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>493</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12060493</pub-id><pub-id pub-id-type="pmid">32481718</pub-id><pub-id pub-id-type="pmcid">PMC7356998</pub-id></element-citation></ref><ref id="B47-pharmaceutics-15-01909"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jinno</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Crison</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Amidon</surname><given-names>G.L.</given-names></name></person-group><article-title>Dissolution of Ionizable Water-Insoluble Drugs: The Combined Effect of pH and Surfactant</article-title><source>J. Pharm. Sci.</source><year>2000</year><volume>89</volume><fpage>268</fpage><lpage>274</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1520-6017(200002)89:2&amp;#x0003c;268::AID-JPS14&amp;#x0003e;3.0.CO;2-F</pub-id><pub-id pub-id-type="pmid">10688756</pub-id></element-citation></ref><ref id="B48-pharmaceutics-15-01909"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sami</surname><given-names>F.</given-names></name><name name-style="western"><surname>Philip</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>K.</given-names></name></person-group><article-title>Effect of Auxiliary Substances on Complexation Efficiency and Intrinsic Dissolution Rate of Gemfibrozil&#8211;&#946;-CD Complexes</article-title><source>AAPS PharmSciTech</source><year>2010</year><volume>11</volume><fpage>27</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1208/s12249-009-9350-y</pub-id><pub-id pub-id-type="pmid">20013079</pub-id><pub-id pub-id-type="pmcid">PMC2850474</pub-id></element-citation></ref><ref id="B49-pharmaceutics-15-01909"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shekunov</surname><given-names>B.</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>E.R.</given-names></name></person-group><article-title>Theoretical Analysis of Drug Dissolution: I. Solubility and Intrinsic Dissolution Rate</article-title><source>J. Pharm. Sci.</source><year>2016</year><volume>105</volume><fpage>2685</fpage><lpage>2697</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2015.12.006</pub-id><pub-id pub-id-type="pmid">26906172</pub-id></element-citation></ref><ref id="B50-pharmaceutics-15-01909"><label>50.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Avdeef</surname><given-names>A.</given-names></name><name name-style="western"><surname>Voloboy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Foreman</surname><given-names>A.</given-names></name></person-group><article-title>5.17&#8212;Dissolution and solubility</article-title><source>Comprehensive Medicinal Chemistry II</source><edition>2nd ed.</edition><person-group person-group-type="editor"><name name-style="western"><surname>Taylor</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Triggle</surname><given-names>D.J.</given-names></name></person-group><publisher-name>Elsevier</publisher-name><publisher-loc>Oxford, UK</publisher-loc><year>2007</year><volume>Volume 5</volume><fpage>399</fpage><lpage>423</lpage></element-citation></ref><ref id="B51-pharmaceutics-15-01909"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hohmann</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kocheise</surname><given-names>F.</given-names></name><name name-style="western"><surname>Carls</surname><given-names>A.</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>J.</given-names></name><name name-style="western"><surname>Haefeli</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>G.</given-names></name></person-group><article-title>Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole</article-title><source>Clin. Pharm.</source><year>2016</year><volume>55</volume><fpage>1535</fpage><lpage>1545</lpage><pub-id pub-id-type="doi">10.1007/s40262-016-0416-1</pub-id><pub-id pub-id-type="pmid">27236320</pub-id></element-citation></ref><ref id="B52-pharmaceutics-15-01909"><label>52.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Food and Drug Administration</collab></person-group><source>Clinical Pharmacology and Biopharmaceutics Review(s). Voriconazole Tablet (50, 200 mg) and Voriconazole for I.V. Injection (200 mg per Vial). Application Number: 21-464, 21-466</source><publisher-name>U.S. Food and Drug Administration</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2003</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021464s000_021466s000_VfendTOC.cfm" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021464s000_021466s000_VfendTOC.cfm</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-07-05">(accessed on 1 July 2023)</date-in-citation></element-citation></ref><ref id="B53-pharmaceutics-15-01909"><label>53.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>European Medicines Agency</collab></person-group><source>Vfend European Public Assessment Report. EPAR&#8212;Scientific Discussion&#8212;Extension</source><publisher-name>European Medicines Agency</publisher-name><publisher-loc>London, UK</publisher-loc><year>2006</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ema.europa.eu/en/medicines/human/EPAR/vfend" ext-link-type="uri">https://www.ema.europa.eu/en/medicines/human/EPAR/vfend</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-07-05">(accessed on 1 July 2023)</date-in-citation></element-citation></ref><ref id="B54-pharmaceutics-15-01909"><label>54.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Therapeutic Goods Administration</collab></person-group><source>Australian Public Assessment Report for Voriconazole. Proprietary Product Name: Vorcon</source><publisher-name>Therapeutic Goods Administration</publisher-name><publisher-loc>Canberra, Australia</publisher-loc><year>2017</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.tga.gov.au/resources/auspar/auspar-voriconazole-0" ext-link-type="uri">https://www.tga.gov.au/resources/auspar/auspar-voriconazole-0</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-07-05">(accessed on 1 July 2023)</date-in-citation></element-citation></ref><ref id="B55-pharmaceutics-15-01909"><label>55.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Pharmaceuticals and Medical Devices Agency</collab></person-group><source>Report on the Deliberation Results (Dayvigo Tablets 2.5 mg, 5 mg, 10 mg)</source><publisher-name>Pharmaceuticals and Medical Devices Agency</publisher-name><publisher-loc>Tokyo, Japan</publisher-loc><year>2019</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0001.html#select4" ext-link-type="uri">https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0001.html#select4</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-07-05">(accessed on 1 July 2023)</date-in-citation></element-citation></ref><ref id="B56-pharmaceutics-15-01909"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Landry</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nakai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ferry</surname><given-names>J.</given-names></name><name name-style="western"><surname>Aluri</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lalovic</surname><given-names>B.</given-names></name><name name-style="western"><surname>Moline</surname><given-names>M.L.</given-names></name></person-group><article-title>Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings from Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy Adults</article-title><source>Clin. Pharmacol. Drug Dev.</source><year>2021</year><volume>10</volume><fpage>153</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1002/cpdd.817</pub-id><pub-id pub-id-type="pmid">32468649</pub-id><pub-id pub-id-type="pmcid">PMC7891412</pub-id></element-citation></ref><ref id="B57-pharmaceutics-15-01909"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ueno</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>T.</given-names></name><name name-style="western"><surname>Aluri</surname><given-names>J.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beuckmann</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Kameyama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Asakura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kusano</surname><given-names>K.</given-names></name></person-group><article-title>Disposition and Metabolism of [<sup>14</sup>C]Lemborexant in Healthy Human Subjects and Characterization of Its Circulating Metabolites</article-title><source>Drug Metab. Dispos.</source><year>2021</year><volume>49</volume><fpage>31</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1124/dmd.120.000229</pub-id><pub-id pub-id-type="pmid">33144331</pub-id></element-citation></ref><ref id="B58-pharmaceutics-15-01909"><label>58.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Food and Drug Administration</collab></person-group><source>Multi-Discipline Review. DAYVIGO (Lemborexant). Application Number: 212028Orig1s000</source><publisher-name>U.S. Food and Drug Administration</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2019</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000TOC.cfm" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000TOC.cfm</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-07-05">(accessed on 1 July 2023)</date-in-citation></element-citation></ref><ref id="B59-pharmaceutics-15-01909"><label>59.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name name-style="western"><surname>Abe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ayata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>N.</given-names></name><name name-style="western"><surname>Akimoto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shikata</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zaima</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>N.</given-names></name></person-group><article-title>Drug Substance of Lemborexant and Medicinal Composition Comprising Same</article-title><source>European Patent</source><patent>Application No. EP 4 059 504 A1</patent><day>21</day><month>September</month><year>2022</year></element-citation></ref><ref id="B60-pharmaceutics-15-01909"><label>60.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Pharmaceuticals and Medical Devices Agency</collab></person-group><source>New Drugs Approved in FY 2012</source><publisher-name>Pharmaceuticals and Medical Devices Agency</publisher-name><publisher-loc>Tokyo, Japan</publisher-loc><year>2012</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html?print" ext-link-type="uri">https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html?print</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-07-05">(accessed on 1 July 2023)</date-in-citation></element-citation></ref><ref id="B61-pharmaceutics-15-01909"><label>61.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Food and Drug Administration</collab></person-group><source>Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations</source><edition>43rd ed.</edition><publisher-name>U.S. Department of Health and Human Services, U.S. Food and Drug Administration</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2023</year><fpage>252</fpage><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book" ext-link-type="uri">https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-07-05">(accessed on 1 July 2023)</date-in-citation></element-citation></ref><ref id="B62-pharmaceutics-15-01909"><label>62.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Food and Drug Administration</collab></person-group><source>Clinical Pharmacology Review(s), Nourianz&#174; (Istradefylline) Tablets. Application Number: 022075Orig1s000</source><publisher-name>U.S. Food and Drug Administration</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2019</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022075Orig1s000TOC.cfm" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022075Orig1s000TOC.cfm</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-07-05">(accessed on 1 July 2023)</date-in-citation></element-citation></ref><ref id="B63-pharmaceutics-15-01909"><label>63.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Pharmaceuticals and Medical Devices Agency</collab></person-group><source>Report on the Deliberation Results (Nouriast Tablets 20 mg)</source><publisher-name>Pharmaceuticals and Medical Devices Agency</publisher-name><publisher-loc>Tokyo, Japan</publisher-loc><year>2013</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0001.html#select14" ext-link-type="uri">https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0001.html#select14</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-07-05">(accessed on 1 July 2023)</date-in-citation></element-citation></ref><ref id="B64-pharmaceutics-15-01909"><label>64.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name name-style="western"><surname>Kuroda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Aoki</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ochiai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Uchida</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kigoshi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Asanome</surname><given-names>K.</given-names></name></person-group><article-title>Microcrystal</article-title><source>U.S. Patent</source><patent>7,541,363 B2</patent><day>2</day><month>June</month><year>2009</year></element-citation></ref><ref id="B65-pharmaceutics-15-01909"><label>65.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Biorelevant.com</collab></person-group><article-title>Biorelevant Media Prep Tool 2022</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://biorelevant.com/?filters=product_type--biorelevant%20media#media_prep_tool_tab" ext-link-type="uri">https://biorelevant.com/?filters=product_type--biorelevant%20media#media_prep_tool_tab</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-05-25">(accessed on 25 May 2022)</date-in-citation></element-citation></ref><ref id="B66-pharmaceutics-15-01909"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holder</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Schaak</surname><given-names>R.E.</given-names></name></person-group><article-title>Tutorial on Powder X-ray Diffraction for Characterizing Nanoscale Materials</article-title><source>ACS Nano</source><year>2019</year><volume>13</volume><fpage>7359</fpage><lpage>7365</lpage><pub-id pub-id-type="doi">10.1021/acsnano.9b05157</pub-id><pub-id pub-id-type="pmid">31336433</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-15-01909-f001" orientation="portrait"><label>Figure 1</label><caption><p>Visualization of the theory behind the r<sub>target</sub> equations.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01909-g001.jpg"/></fig><fig position="float" id="pharmaceutics-15-01909-f002" orientation="portrait"><label>Figure 2</label><caption><p>Decision wheel for selection of the appropriate r<sub>target</sub> equation(s) for a given case. The figure should be read from the outermost shell inwards. Detailed equations are presented in <xref rid="pharmaceutics-15-01909-t002" ref-type="table">Table 2</xref>. Further details are provided in the above text.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01909-g002.jpg"/></fig><fig position="float" id="pharmaceutics-15-01909-f003" orientation="portrait"><label>Figure 3</label><caption><p>Chemical structures of (<bold>a</bold>) voriconazole, (<bold>b</bold>) lemborexant and (<bold>c</bold>) istradefylline (drawn with MedChem Designer&#8482; version 5, Simulations Plus Inc., Lancaster, CA, USA).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01909-g003.jpg"/></fig><fig position="float" id="pharmaceutics-15-01909-f004" orientation="portrait"><label>Figure 4</label><caption><p>Relationship between IDR in &#181;g/min/cm<sup>2</sup> and C<sub>S</sub> in &#181;g/mL (both measured in FaSSIF V1) using logarithmic coordinates. IDRs of voriconazole and lemborexant were measured with the disk dissolution method, the IDR of istradefylline was derived from powder dissolution experiments. Disk IDR and solubility data of an additional API (voxelotor) in the same medium were added to support the correlation. Error bars fall within the data icons.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01909-g004.jpg"/></fig><fig position="float" id="pharmaceutics-15-01909-f005" orientation="portrait"><label>Figure 5</label><caption><p>Particle size dependent dissolution profiles of 10 mg lemborexant tablets in (<bold>a</bold>) 0.1 M hydrochloric acid, and (<bold>b</bold>) pH 6.8 (Japanese Pharmacopoeia). Adapted from ref. [<xref rid="B59-pharmaceutics-15-01909" ref-type="bibr">59</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01909-g005.jpg"/></fig><fig position="float" id="pharmaceutics-15-01909-f006" orientation="portrait"><label>Figure 6</label><caption><p>(<bold>a</bold>) C<sub>max</sub>, and (<bold>b</bold>) AUC of unpulverized istradefylline (average particle size = 181 &#181;m) and istradefylline microcrystals (average particle size = 11 &#181;m) suspended in 0.5 <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic> % methylcellulose aqueous vehicle (0.3 mg/mL) and orally administered to male rats (body weight: 209 to 233 g) at the dose of 10 mL/kg. Data are presented as the mean &#177; SEM. Adapted from ref. [<xref rid="B64-pharmaceutics-15-01909" ref-type="bibr">64</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01909-g006.jpg"/></fig><table-wrap position="float" id="pharmaceutics-15-01909-t001" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-01909-t001_Table 1</object-id><label>Table 1</label><caption><p>Key assumptions and their mathematical formulation for the derivation of the dissolution rate constant (k<sub>diss</sub>) from the Noyes&#8211;Whitney/Nernst&#8211;Brunner equation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Assumption</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mathematical Formulation</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Total powder surface area of a monodispersed spherical particle population <sup>1</sup> [<xref rid="B16-pharmaceutics-15-01909" ref-type="bibr">16</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm31" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">N</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>4</mml:mn><mml:mi mathvariant="sans-serif">&#960;</mml:mi><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>&#183;</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:mfrac><mml:mi mathvariant="sans-serif">&#960;</mml:mi><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msup><mml:mi mathvariant="sans-serif">&#961;</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dissolution under sink conditions</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><inline-formula><mml:math id="mm32" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> i.e., <inline-formula><mml:math id="mm33" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aqueous boundary layer (ABL) thickness equals initial particle radius for particles with r<sub>0</sub> &lt; 30 &#181;m [<xref rid="B17-pharmaceutics-15-01909" ref-type="bibr">17</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm34" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ABL thickness equals constant value for particles with r<sub>0</sub> &#8805; 30 &#181;m [<xref rid="B3-pharmaceutics-15-01909" ref-type="bibr">3</xref>,<xref rid="B18-pharmaceutics-15-01909" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-15-01909" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceutics-15-01909" ref-type="bibr">20</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">e.g., <inline-formula><mml:math id="mm35" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>30</mml:mn><mml:mo>&#160;</mml:mo><mml:mi mathvariant="normal">&#181;</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>
</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> where A<sub>p</sub> is the surface area of a single particle and N<sub>0</sub> is the number of particles.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-15-01909-t002" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-01909-t002_Table 2</object-id><label>Table 2</label><caption><p>Summary of r<sub>target</sub> equations applying different approaches and h<sub>particle</sub> assumptions.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Approach</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Based on</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">r<sub>target</sub> Equation</th></tr><tr><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">h<sub>particle</sub> = r<sub>0</sub></th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">h<sub>particle</sub> &#8800; r<sub>0</sub></th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.1</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Dissolution/<break/>Transit<break/>balance</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dn and C<sub>S</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Equation (7) <sup>1</sup>:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm36" overflow="scroll"><mml:mrow><mml:mrow><mml:msqrt><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi></mml:mrow></mml:mfrac></mml:msqrt></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Equation (8) <sup>2</sup>:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm37" overflow="scroll"><mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dn and IDR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Equation (14) <sup>2</sup>:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm38" overflow="scroll"><mml:mrow><mml:mrow><mml:msqrt><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">k</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi></mml:mrow></mml:mfrac></mml:msqrt></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Equation (15) <sup>2</sup>:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm39" overflow="scroll"><mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">k</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.3</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Dissolution/<break/>Permeation<break/>balance</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">k<sub>diss</sub>/k<sub>perm</sub> and C<sub>S</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Equation (20) <sup>2</sup>:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm40" overflow="scroll"><mml:mrow><mml:mrow><mml:msqrt><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:msub><mml:mrow><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">F</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi><mml:msub><mml:mrow><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:msqrt></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Equation (21) <sup>2</sup>:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm41" overflow="scroll"><mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">F</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi><mml:msub><mml:mrow><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">k<sub>diss</sub>/k<sub>perm</sub> and IDR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Equation (22) <sup>2</sup>:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm42" overflow="scroll"><mml:mrow><mml:mrow><mml:msqrt><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">k</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">F</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi><mml:msub><mml:mrow><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:msqrt></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Equation (23) <sup>2</sup>:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm43" overflow="scroll"><mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">k</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">F</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi><mml:msub><mml:mrow><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A<sub>powder</sub> and IDR</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Equation (26) <sup>2</sup>: </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm44" overflow="scroll"><mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">F</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi mathvariant="sans-serif">&#961;</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Ref. [<xref rid="B9-pharmaceutics-15-01909" ref-type="bibr">9</xref>].<sup>2</sup> Novel r<sub>target</sub> equation.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-15-01909-t003" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-01909-t003_Table 3</object-id><label>Table 3</label><caption><p>Experimental and literature pK<sub>a</sub> values of voriconazole, lemborexant and istradefylline.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Method for pK<sub>a</sub> Determination</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Voriconazole</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Lemborexant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Istradefylline</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fast UV (<xref rid="sec3dot2dot1-pharmaceutics-15-01909" ref-type="sec">Section 3.2.1</xref>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- <sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.18 &#177; 0.05 <sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- <sup>1</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Literature pK<sub>a</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.76 <sup>3</sup> [<xref rid="B32-pharmaceutics-15-01909" ref-type="bibr">32</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;3.50 [<xref rid="B33-pharmaceutics-15-01909" ref-type="bibr">33</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.78 <sup>3</sup> [<xref rid="B31-pharmaceutics-15-01909" ref-type="bibr">31</xref>,<xref rid="B34-pharmaceutics-15-01909" ref-type="bibr">34</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Evidence of additional low pK<sub>a</sub> outside the calibration limit (pH 2 to 12). <sup>2</sup> Low absorbance (&lt;0.30 abs units) associated with the pK<sub>a</sub>, value should be treated with caution. <sup>3</sup> Method of determination not disclosed.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-15-01909-t004" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-01909-t004_Table 4</object-id><label>Table 4</label><caption><p>Experimental and literature logD<sub>pH7.4</sub>/logP <sup>1</sup> of voriconazole, lemborexant and istradefylline.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Method for logD<sub>pH7.4</sub>/logP <break/>Determination</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Voriconazole</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Lemborexant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Istradefylline</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shake-flask logD<sub>pH7.4</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.66 &#177; 0.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.04 &#177; 0.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.96 &#177; 0.03</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Literature logP <sup>2</sup>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.80 [<xref rid="B32-pharmaceutics-15-01909" ref-type="bibr">32</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.70 [<xref rid="B33-pharmaceutics-15-01909" ref-type="bibr">33</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.5&#8211;3.6 [<xref rid="B34-pharmaceutics-15-01909" ref-type="bibr">34</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> As none of the three compounds are ionized at pH 7.4, the logP and logD<sub>pH7.4</sub> are identical. <sup>2</sup> Method of determination not disclosed.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-15-01909-t005" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-01909-t005_Table 5</object-id><label>Table 5</label><caption><p>Results of the thermodynamic solubility and IDR studies including solid state analyses, SLADs and rDCS classifications for 5, 50, 500 mg and a usual dose.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">API</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">C<sub>S</sub>&#160;<sup>1</sup><break/>FaSSIF V1 [&#181;g/mL]</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">IDR <sup>a</sup><break/>FaSSIF V1 [&#181;g/min/cm<sup>2</sup>]</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Cryst. Form</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">SLAD</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">rDCS Classification</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 mg</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50 mg</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">500 mg</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Usual dose</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Voriconazole</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">827 &#177; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84.8 &#177; 1.4 <sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">B <sup>4</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1810</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIa</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I<sub>200mg</sub></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lemborexant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23.3 &#177; 0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.99 &#177; 0.09 <sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CS2 <sup>4</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIa/b</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIb</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I<sub>10mg</sub></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Istradefylline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.59 &#177; 0.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.302 &#177; 0.010 <sup>3</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I <sup>5</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIa</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIb</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIb</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIb<sub>20mg</sub></td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> pH 6.50 &#177; 0.05. <sup>2</sup> Measured with the disk dissolution method. <sup>3</sup> Measured with the powder dissolution method. <sup>4</sup> Based on the solid state analysis after the solubility study, disk compression, and disk dissolution. <sup>5</sup> Based on the solid state analysis after the solubility study. <sup>a</sup> Intrinsic dissolution rate</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-15-01909-t006" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-01909-t006_Table 6</object-id><label>Table 6</label><caption><p>Measured Caco-2 P<sub>app</sub> and derived P<sub>eff</sub> values for voriconazole, lemborexant and istradefylline.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Permeability Measure</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Voriconazole</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Lemborexant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Istradefylline</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P<sub>app</sub>(A&#10233;B) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[&#215;10<sup>&#8722;6</sup> cm/s]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27.3 &#177; 1.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26.7 &#177; 1.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.2 &#177; 1.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P<sub>app</sub>(A&#10233;B) + inhibitor </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[&#215;10<sup>&#8722;6</sup> cm/s]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.0 &#177; 1.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.2 &#177; 0.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31.2 &#177; 1.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P<sub>app</sub>(B&#10233;A) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[&#215;10<sup>&#8722;6</sup> cm/s]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43.5 &#177; 0.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41.8 &#177; 1.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28.3 &#177; 16.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P<sub>app</sub>(B&#10233;A) + inhibitor </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[&#215;10<sup>&#8722;6</sup> cm/s]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40.4 &#177; 1.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.0 &#177; 0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43.7 &#177; 18.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Estimated human P<sub>eff</sub>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[&#215;10<sup>&#8722;4</sup> cm/s]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.66</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-15-01909-t007" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-01909-t007_Table 7</object-id><label>Table 7</label><caption><p>Results for k<sub>diss</sub> and k<sub>perm</sub> using the rDCS approach by Rosenberger et al. [<xref rid="B10-pharmaceutics-15-01909" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-15-01909" ref-type="bibr">11</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Voriconazole</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Lemborexant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Istradefylline</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">k<sub>diss</sub>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[min<sup>&#8722;1</sup>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.56 &#215; 10<sup>&#8722;3</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.80 &#215; 10<sup>&#8722;4</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.73 &#215; 10<sup>&#8722;5</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">k<sub>perm</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[min<sup>&#8722;1</sup>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.19 &#215; 10<sup>&#8722;2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.14 &#215; 10<sup>&#8722;2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.38 &#215; 10<sup>&#8722;2</sup></td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-15-01909-t008" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-01909-t008_Table 8</object-id><label>Table 8</label><caption><p>Calculated r<sub>target</sub> values for voriconazole, lemborexant and istradefylline using the approaches shown in <xref rid="pharmaceutics-15-01909-f001" ref-type="fig">Figure 1</xref>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Approach</th><th rowspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Based on</th><th colspan="9" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">r<sub>target</sub> [&#181;m]</th></tr><tr><th colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Voriconazole (200 mg)</th><th colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Lemborexant (10 mg)</th><th colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Istradefylline (20 mg)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">h<sub>particle</sub> = <break/>r<sub>0</sub></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">h<sub>particle</sub> = <break/>30 &#181;m</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">h<sub>particle</sub> = <break/>h<sub>disk</sub>&#160;<sup>1</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">h<sub>particle</sub> = <break/>r<sub>0</sub></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">h<sub>particle</sub> = <break/>30 &#181;m</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">h<sub>particle</sub> = <break/>h<sub>disk</sub>&#160;<sup>1</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">h<sub>particle</sub> = <break/>r<sub>0</sub></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">h<sub>particle</sub> = <break/>30 &#181;m</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">h<sub>particle</sub> = <break/>h<sub>disk</sub>&#160;<sup>1</sup></th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Dissolution/<break/>transit balance</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dn <break/>and C<sub>S</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">124</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">516</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">364</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.94</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.67</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dn <break/>and IDR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">123</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">502</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">354</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.81</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.97</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.46</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Dissolution/<break/>permeation balance</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">k<sub>diss</sub>/k<sub>perm</sub> and C<sub>S</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">118</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">83.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.73</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.92</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">k<sub>diss</sub>/k<sub>perm</sub> and IDR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">115</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.43</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A<sub>powder</sub> and IDR</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81.0</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<italic toggle="yes">-</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.06</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.43</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> h<sub>disk</sub> = 42.5 &#181;m (voriconazole), 40.7 &#181;m (lemborexant), 40.7 &#181;m (istradefylline).</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>